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The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial found no substantial 
difference in HIV acquisition risk between women randomised to injectable depot 
medroxyprogesterone acetate (DMPA-IM), copper intrauterine device (IUD) or the 
levonorgestrel (LNG) implant. However, it remains unknown whether these contraceptives 
increase HIV risk relative to other forms of contraception or no contraception. This study 
investigated the impact of DMPA-IM, copper IUD and LNG implant on cervicovaginal 
inflammatory profiles previously associated with HIV acquisition, among a sub-cohort of 
ECHO participants.  
This study included 167 ECHO participants at the Setshaba Research Centre in Pretoria and 
MatCH Research Unit in Durban, South Africa. Eleven cytokines and antimicrobial peptides 
were measured in lateral vaginal wall swabs in duplicate using Luminex. Differences in 
baseline cytokine profiles were assessed using demographic data, including site, age, body 
mass index (BMI) and sexually transmitted infection (STI) status. Changes in cytokine 
concentrations were assessed using Wilcoxon signed ank test. Fold changes in cytokine 
concentrations were compared between arms using Mann-Whitney U test. P-values were 
adjusted for multiple comparisons using a false discovery rate procedure. Overall cytokine 
profiles were compared using principal components analysis and unsupervised hierarchical 
clustering. Mixed effects linear regression was used for longitudinal analysis and multinomial 
logistic regression was used to adjust for potential confounders that were assessed at baseline.  
Concentrations of IL-6 and MIP-3α were significantly higher in women enrolled at the 
Setshaba Research Centre compared to the MatCH Research Unit. Several immune mediators 
were elevated in younger women and this trend was significant for the pro-inflammatory IL-
1β and the chemokines IL-8 and MIP-1α. Women that were seropositive for herpes simplex 
virus type 2 (HSV-2) had significantly lowerconcentrations of MIP-1α. The copper IUD and 
LNG implant were associated with rapid increases in inflammatory markers following 
contraceptive initiation. Pro-inflammatory IL-1β and IL-6 and chemotactic IL-8, IP-10, MIP-
1⍺ and MIP-1β were significantly elevated one month following copper IUD insertion. No 
changes were evident at one-month post LNG implant insertion, however at three months, 
TNF-⍺, IP-10, MIP-3⍺ and SLPI were significantly raised relative to baseline. No significant 
changes in immune mediator concentrations were detected following DMPA-IM initiation but 
the trend was towards a decrease, particularly for SLPI. After adjusting for potential 
confounders, including site, age and infection status with chlamydia, gonorrhoea and HSV-2, 
IL-6 and IP-10 were significantly elevated in the copper IUD compared to the DMPA-IM arm 
at months 1 and 3, while IP-10 and SLPI were higher in the LNG implant arm at month 3 
compared to the DMPA-IM arm. 
The copper IUD and the LNG implant are associated with increased cervicovaginal 
inflammatory markers that have been linked to HIV infection risk and the chemokine IP-10 
appears to play a central role. Recent studies have demonstrated the importance of the interplay 
between inflammation, the microbiome, contraception and HIV risk. Continued research to 







With a total of 270 000 new HIV infections reported in South Africa in 2017, the country 
remains the most affected by the virus to this day1. Young women and adolescent girls, in 
particular, account for the large majority of incident infections in this region every year and it 
is estimated that they are twice as likely to acquire the virus as their male peers1.  Although a 
portion of this high vulnerability among women in South Africa can be explained by certain 
socio-cultural behavioural patterns2,3, it is now recognized that biological factors also play an 
important role4–6.  
Immunity in the Female Genital Tract 
Transmission rates of HIV, in the case of unprotected receptive vaginal intercourse, are 
relatively low at an estimated 0.1% per coital act in healthy individuals7. This low rate of 
transmission is largely due to the cervicovaginal epithelium, a transition barrier that separates 
the external environment from the internal body, offering protection through both anatomical 
and biological components8. While the upper part of the genital tract, the endocervix, is covered 
by a single layer of columnar epithelium, the vagina and the ectocervix, which make up the 
lower genital tract, are characterized by the presence of stratified squamous epithelium9. 
Covering these surfaces is an additional layer of differentiated epithelial cells known as the 
stratum corneum10. The integrity of the epithelium is promoted by the presence of proteins 
known as tight and adherens junctions, which decrease the permeability of the barrier11. 
Interestingly, tight junctions in the lower reproductive tract are mostly found between basal 
epithelial cells and are absent from superficial layers, contributing to an environment which is 
more prone to penetration by pathogens, including HIV12. Covering mucosal surfaces is a layer 
of mucus, a major component that affects pathogen transmission. Mucus acts as a physical 
barrier13 and contains a high concentration of soluble proteins, such as antimicrobial agents 
and antiproteases, which aid in the protection against pathogens14,15. Protection in the lower 
genital tract is further enhanced by the presence of the commensal microbiota which is 
dominated by Lactobacillus species in women with optimal microbiota16. Through the 
production of lactic acid, the commensal bacteria maintain the acidic pH of the mucus. The 
production of hydrogen peroxide as well as bacteriocins further contributes to the antagonistic 
interaction of Lactobacillus species with pathogenic bacteria and viruses by directly inhibiting 
their growth17. While the above-mentioned components are an effective first-line defence 
mechanism against invading organisms, genital inflammation occurs following infection or 
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outgrowth of pathogenic/non-optimal microbes. Epithelial cells are largely involved in the 
initiation of inflammatory responses that form part of the biological defence mechanisms of 
the female genital tract (FGT)11. The release of cytokines through activation of pattern 
recognition receptors forms a crucial part of this response as these soluble factors are involved 
in stimulating a response from a variety of immune cells11.   
Inflammation and HIV Risk 
Although inflammation is an indispensable part of the immune response against pathogens and 
thus plays an important role in maintaining health, it has previously been shown that elevated 
levels of inflammatory cytokines in the FGT are linked to an increased risk of HIV 
acquisition4,18,19. Strikingly, the risk of HIV infection was three times higher in women with 
elevated levels of at least five of nine mucosal pro-inflammatory cytokines, including the 
macrophage inflammatory protein (MIP)-1α, MIP-1β, interferon gamma-induced protein (IP)-
10, interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, IL-1α, IL-1β, IL-6 as well 
as tumor necrosis factor (TNF)-α4. In line with this, Mlisana, et al. also reported an association 
between higher concentrations of IL-1β, IL-6 and IL-8 in cervicovaginal lavage samples and 
an increased risk of HIV infection20. A recent study by Morrison, et al. showed that elevated 
levels of RANTES (regulated on activation, normal T cell expressed and secreted) as well as 
decreased levels of secretory leukocyte protease inhibitor (SLPI) were associated with HIV 
seroconversion18. A recent study further found that inflammation in the FGT significantly 
reduced the effectiveness of tenofovir gel in preventing HIV acquisition19. These findings 
suggest that some biomedical HIV prevention methods may be ineffective in the presence of 
genital inflammation and a deeper understanding of genital inflammation in the context of HIV 
risk is crucial.  
HIV relies on the presence of immune target cells, specifically CD4+ cells, to replicate as this 
is the entry receptor. In general, pro-inflammatory cytokines, as well as chemokines, facilitate 
the activation, differentiation and recruitment of these target cells, thereby creating favourable 
conditions for the virus9. More specifically, IP-10, MIP-1α, MIP-1β as well as RANTES are 
chemokines that have been found to increase HIV risk by recruiting HIV target cells9,18,21. MIP-
1α, MIP-1β and RANTES bind directly to the C-C chemokine receptor type 5 (CCR5), one of 
the HIV coreceptors, and therefore specifically target CCR5+ cells for recruitment to the genital 
mucosa22. In the context of sexual transmission, HIV infection is preferentially established by 
R5-tropic viruses, highlighting the critical role of this coreceptor23. It has thus been proposed 
that high concentrations of these chemokines in the FGT lead to the increased recruitment of 
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HIV target cells, in turn increasing the probability of infection. In addition, pro-inflammatory 
cytokines promote the expression of nuclear factor (NF)-κB. This influential transcription 
factor, in turn, directly binds to the HIV promoter and enhances its transcriptional capacity, 
thereby promoting productive infection further24.  
Much research has linked increased inflammation in the FGT to disturbances in epithelial 
barrier functions. Arnold, et al. showed that proteins associated with tissue remodelling 
processes, such as those involved in regulating the organization of the actin cytoskeleton, were 
up-regulated in individuals with an overall inflammatory profile25. Simultaneously, proteins 
that indicate mucosal barrier integrity, including a key marker of late epidermal differentiation 
known as cornulin26, were found to be down-regulated. According to these results, a model was 
suggested in which inflammation leads to increased tissue remodelling at the expense of 
mucosal barrier integrity, suggesting another possible mechanism underlying the relationship 
between inflammation and heightened HIV risk25. Furthermore, neutrophil-associated proteins, 
especially certain proteases, were positively associated with inflammation. Linked to their role 
in endometrial degradation during menstruation27, these proteases may be involved in 
disrupting the mucosal barrier and thus enhancing immune cell migration and increasing the 
access of HIV to target cells25. Further validating this theory is the result of a previous study 
which discovered an increase in antiproteases, belonging to the family of serpins and elafins, 
to be associated with HIV resistance in a cohort of sex workers from Kenya28. Additionally, a 
direct relationship between pro-inflammatory cytokines and disruption of epithelial barrier 
function has been demonstrated using in vitro models29. Sexual intercourse itself can result in 
micro-abrasions in the FGT mucosa, causing increased inflammation accompanied by 
increased wound healing processes and the recruitment of immune cells30. Exposure to semen 
further contributes to impaired immune function in the FGT. The pH of normal semen lies 
between 7.2 and 7.8, making it more alkaline than the acidic environment of the vagina in 
women with optimal microbiota31. Its presence therefore increases the vaginal pH. The acidic 
mucus of the vagina has been shown to slow the rate of HIV diffusion by interfering with the 
negatively charged surface of the virus. A shift to a more alkaline environment allows HIV to 
retain its negative charge, resulting in a higher rate of diffusion and likelihood of infection32,33.  
Additionally, semen exposure increases levels of pro-inflammatory cytokines, including IL-6, 
IL-8 and IL-1β, and has been associated with an increase in local HIV target cells34,35. 
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The Role of Bacterial Vaginosis and Sexually Transmitted Infections in Genital 
Inflammation and HIV Risk 
Sexually transmitted infections (STIs) have been identified as major causes of elevated 
cytokine concentrations in the genital tract36. Both viral infections, such as herpes simplex virus 
2 (HSV-2), and bacterial infections, including Chlamydia trachomatis and Neisseria 
gonorrhoeae, are highly prevalent in sub-Saharan Africa, most likely contributing to the 
disproportionate vulnerability of this population to HIV37. Adolescent females in South Africa 
bear a particularly high burden of STIs, with studies reporting rates of C. trachomatis 
prevalence of up to 42%38. HSV-2 has been identified as the most influential infection with 
regards to HIV vulnerability. In a study conducted by Masese, et al., the overall risk of HIV 
infection in a cohort of African women was predominantly attributed to HSV-2 infection5. 
While ulcerative lesions directly disrupt the mucosal barrier, HIV target cell concentrations at 
the mucosa are increased during HSV-2 infection, regardless of the presence of lesions39. 
Additionally, subclinical levels of inflammation in the genital mucosa can persist for months 
after lesion resolution40. 
Although not considered to be an  STI, bacterial vaginosis (BV) is a sexually-associated 
condition that causes high levels of inflammation in the FGT41. BV occurs when the genital 
microbiota shifts from predominantly lactobacilli to a more diverse, non-optimal population 
including anaerobic Gardnerella, Prevotella and Atopobium species42. Younger women 
generally have a greater prevalence of these anaerobic bacteria, while more favourable bacteria 
become more abundant with age43. Clinically, BV is defined using the Amsel criteria44 or the 
Nugent score45. The Amsel criteria is based on the presence of several clinical signs, including 
a vaginal pH higher than 4.5, detection of fishy odour and the presence of clue cells. Nugent 
scoring involves Gram staining of a vaginal smear to quantify Lactobacillus, Mobiluncus and 
coccobacilli. Scores range from optimal (0-3), through intermediate (4-6), to BV positive (7-
10). However, the development of high-throughput sequencing techniques, such as 16S rRNA 
sequencing, has enabled more detailed characterisation of bacterial populations in the FGT 
compared to these traditional methods46. Dysbiosis is often difficult to define and some BV-
associated bacteria are detected in BV negative women. For example, Gardnerella vaginalis is 
a bacterium that can be present as a commensal and is only involved in disease when present 
in abnormally high abundance47. In addition, four different subtypes of the bacterium have 
recently been identified and their prevalence among BV positive women varies. While clade 
one, two and three are prevalent in women with BV, clade four G. vaginalis is commonly seen 
in women without BV48. 
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The vaginal microbiota differs greatly across individuals and may be influenced by many 
factors, including ethnicity49. A recent study showed that the HIV acquisition rates of young 
South African women with highly diverse genital microbiota and a low abundance of 
Lactobacillus species were over four-fold higher than observed in women with L. crispatus 
dominance50. Furthermore, the above described microbial community type, including diverse 
genital microbiota and a low abundance of Lactobacillus species, was associated with elevated 
cytokine levels as well as an increased proportion of HIV target cells in the FGT. Due to the 
frequently asymptomatic nature of the condition, BV oftentimes remains undiagnosed and even 
if treatment occurs, recurrent episodes are common51. Compared to the 90% of women in 
developed countries who have Lactobacillus-dominant vaginal communities, South African 
women frequently have low Lactobacillus abundance coupled with a lack of clinical BV 
symptoms38. Furthermore, if the vaginal microbiome of South African women is dominated by 
Lactobacillus spp., it commonly tends to be L. iners52. L. iners is frequently present in women 
with non-optimal vaginal microbiota and whether it plays a protective role in the FGT remains 
uncertain53. Compared to other Lactobacillus species, L. iners has a smaller genome and it has 
been speculated that this could be indicative of a more symbiotic or parasitic relationship with 
its host53. Additionally, the genome of L. iners encodes inerolysin, a pore-forming toxin that is 
related to vaginolysin, produced by G. vaginalis 53. This has led to the belief that beyond a lack 
of protection, this specific species of Lactobacillus may even be involved in the onset and 
persistence of BV54. Importantly, even when BV is asymptomatic, it causes dramatic increases 
in pro-inflammatory cytokines, although down-regulations of some mediators, including 
chemokines, may occur55. 
The Role of the Hormonal Cycle in Inflammation and HIV Risk 
While there is substantial evidence supporting the concept that STIs and BV shift the vaginal 
environment to a more pro-inflammatory milieu, the role of sex hormones, whether 
endogenous or synthetic, remains controversial. Sex hormones are heavily involved in the 
regulation of immunity in the FGT by maintaining the balance between protection from 
pathogens and at the same time allowing for the reproductive functions of the FGT. This 
delicate balance is largely facilitated by oestradiol and progesterone, two hormones produced 
periodically by the ovaries56. The menstrual cycle itself can be divided into four stages: the 
menstrual phase, the proliferative (or follicular) phase, the mid-cycle and lastly, the secretory 
(or luteal) phase. Oestradiol levels rise throughout the proliferative phase and peak before mid-
cycle. This is followed by a rapid increase in luteinizing hormone, which is needed for 
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ovulation to occur. Peak concentrations of progesterone are observed at the mid-secretory 
phase. The fluctuation of hormone levels is thought to play a role in HIV acquisition risk. More 
specifically, the secretory phase of the menstrual cycle has previously been referred to as the 
“window of vulnerability”, during which women are thought to be at a higher risk of 
contracting the virus56. This theory is based mostly on epidemiological observations and results 
differ greatly with some supporting57 and others opposing the theory58.  
Interestingly, a recent study conducted by Villegas, et al. showed that ectocervical tissues 
obtained from women in the secretory phase of the menstrual cycle had an overall higher pro-
inflammatory profile than those harvested during the proliferative phase, with several 
important inflammatory markers, including IL-6, IL-7 and IL-8, elevated59. These changes are 
potentially relevant to HIV transmission as it has been shown that IL-6 increases HIV 
expression in vitro 60, while high levels of IL-8 increased HIV infection up to 8-fold in cervical 
explant tissue61. Additionally, observational studies have linked high concentrations of genital 
IL-6 and IL-8 to an increased risk of HIV infection4,20.   
Furthermore, HIV shedding in the presence of elevated IL-6 levels was heightened in 
cervicovaginal lavage obtained from HIV-infected women58. High levels of IL-7, on the other 
hand, have been linked to increased CD4+ T cell proliferation as well as inhibited T cell 
apoptosis in ectocervical explants. This, in turn, increased the availability of HIV target cells, 
thus risk of infection when tissues were exposed to the virus62. Although the role of IL-8 in 
HIV risk is less well established, generally the cytokine has chemotactic effects on neutrophils 
and macrophages and thus increases inflammation and target cell availability63,64. Interestingly, 
IL-8 signalling was one of the most notable pathways associated with the secretory phase of 
the menstrual cycle61,65. This suggests that this cytokine, among others, may play a crucial role 
in the context of HIV acquisition.  Additionally, progesterone is able to alter the humoral 
immunity of an individual, with reports demonstrating decreased IgG and IgA concentrations 
in vaginal secretions during the luteal phase66. The secretory phase of the menstrual cytokine 
has also been associated with reduced epithelial barrier function. Birse et al., recently 
demonstrated an association between proteins involved in tissue remodelling and the luteal 
phase of the menstrual cycle. Cell-to-cell adhesion proteins as well as certain anti-proteases 
were reduced during the secretory phase, indicating that epithelial barrier function may play a 
role in hormone-related mechanisms of increased HIV susceptibility65. Furthermore, thinning 
of the vaginal epithelium has been observed in response to high doses of progesterone during 
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the luteal phase of the menstrual cycle in primates67. These changes may alter susceptibility to 
HIV acquisition. 
Contraceptives and HIV risk 
Contraception has many benefits, including reduced maternal and infant mortality and 
morbidity, the empowerment of women as well as a reduction in the number of HIV-infected 
children68. A wide variety of Long-acting hormonal and non-hormonal contraceptive methods 
are currently available and represent a popular choice among women due to their longevity and 
low failure rate69. These include: 1) rings, 2) implants, 3) IUDs (intrauterine devices) and 4) 
injectables. Combined oral contraceptive (COCs) pills and IUDs are two of the most prevalent 
HCs used by women worldwide70. In 2015, approximately 14% of married or in-union women 
worldwide relied on an intrauterine device for protection, while 9% used COCs70. Studies have 
shown that COCs may have beneficial effects on the vaginal microbiome by increasing L. 
crispatus abundance and thus decreasing rates of BV71. While some women in low- and 
middle-income countries use COCs, the majority rely on long-acting injectables for 
contraception70. 
Injectables 
Injectables are a popular choice among hormonal contraceptives (HCs). In South Africa, 
approximately 24% of women use injectables with the three-monthly intramuscular injection 
of 150 mg depomedroxyprogesterone acetate (DMPA-IM) being the most popular choice70. To 
this day, high rates of intimate partner violence, especially in the form of female oppression, 
drive the high use of this injectable due to its relative longevity and discrete administration72. 
While one of the most popular choices, DMPA-IM is not the only method of progestin-based 
long-acting HC, with other types varying in the dose and type of progesterone-like compounds, 
synthetic analogues of the endogenous hormone progesterone. As increases in progesterone 
levels after ovulation cause changes in the endometrium that facilitate egg implantation, the 
use of synthetic analogues transforms the endometrium into secretory phase tissue and 
ovulation is prevented. Additionally, thinning of the endometrium is initiated and glycogen 
secretion is reduced, causing the cervical mucus to become thicker and more viscous and thus 
preventing sperm penetration and the implantation of embryos73.  
The frequent usage of DMPA-IM in South Africa overlaps with the disproportionally high 
burden of HIV observed in these women and epidemiological data suggests that use of the 
injectable may increase HIV risk by 40-50%74,75. However, the contribution of HCs, in 
particular DMPA-IM, to HIV risk is controversial among scientists76. Recently a large 
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randomized control trial, the Evidence for Contraceptive Options and HIV Outcomes (ECHO), 
was conducted to further evaluate the risk of HIV infection associated with the use of DMPA-
IM. The results of the trial did not demonstrate statistically significant differences in HIV risk 
between women using 150-IM compared to those using the copper intrauterine device (Cu-
IUD) or the levonorgestrel (LNG) implant. However, the study was only powered to detect an 
increased risk above 50%. An analysis adjusted for covariates suggested that the use of DMPA-
IM may increase HIV risk by 29% compared to the LNG implant [hazard ratio: 1.29 (0.98 – 
1.71, p=0.060)], which would contribute substantially to HIV incidence77. It therefore remains 
unknown whether these contraceptives increase HIV risk relative to other forms of 
contraception or no contraception78.   
Several studies have suggested the possible effect of DMPA on HIV risk may be dependent on 
the dose administered73. Interestingly, different contraceptives differ greatly with regards to 
serum concentration, both at peak and trough levels. The dosage of progestins, route of 
administration, as well as the metabolism of the patient are only three of many factors that 
influence serum levels at any given time. In the context of increased HIV risk, it is highly 
important to note that no information is available on tissue concentrations of progestins. Sayana 
Press, also known as DMPA-SQ or DMPA-SC, is a lower dose formulation (104 mg) which is 
administered in a subcutaneous manner. It has become apparent that the 150 mg dose of DMPA 
usually administered is extremely high and the 31% lower dose delivered in DMPA-SQ still 
inhibits ovulation79. As this lower dose formulation has potential benefits compared to DMPA-
IM, its introduction is predicted to increase DMPA usage worldwide73. Norethisterone 
enanthate, usually referred to as NET-EN or Nur-Isterate, is another popular injectable 
contraceptive. Similar to DMPA, it is injected intramuscularly every two months and is 
primarily used in South Africa. An intramuscular dose of 200mg NET has similar contraceptive 
efficacy to DMPA-IM80.  
In response to increasing epidemiological evidence and rising concerns, the World Health 
Organization changed the criteria for the use of DMPA-IM, DMPA-SC and NET-EN from no 
restriction (medical eligibility criteria for contraceptive use category 1) to category 2, 
indicating that the benefits generally outweigh the risks. However, based on the results of the 
ECHO trial, which did not report on an increased risk of HIV associated with DMPA-IM use 
when compared to the LNG implant and non-hormonal copper IUD, these contraceptives have 
now been moved back to category 1. Despite this, the possible contribution of these 
contraceptives to HIV risk remains controversial among researchers in the field81. Additionally, 
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aside from the question of altered HIV risk, it remains unknown whether these contraceptives 
cause vaginal microbiome and immune changes that may influence reproductive health. 
Associations between HC use and immunological factors, the microbiome and HIV risk thus 
warrant further investigation. 
Intrauterine devices 
IUDs are amongst the most popular contraceptive methods, with the copper IUD having an 
efficacy of > 99%82. Data evaluating associations between copper IUD use and HIV risk are 
extremely limited and weak83. Although two older studies have suggested a possible link84,85, 
the majority of existing reports indicate that the copper IUD does not increase a woman’s risk 
of acquiring the virus86–88. It is important to note that there are no recent studies that have 
investigated further.  
Implants 
Levonorgestrel (LNG) implants represent an additional form of HC. Data for these types of 
contraceptives suggests their usage does not significantly increase the risk of HIV acquisition, 
however there is currently minimal data 74. Similar to the copper IUD, data on HIV risk in 
implant users are sparse. Early studies in rhesus macaques suggested that progestin-only 
implants enhance transmission of Simian Immunodeficiency Virus (SIV) and early viral load89. 
More recent studies, however, have not identified a link between an increased HIV 
transmission risk and the use of implant contraceptives, specifically the LNG implant that is 
typically sold under the name Jadelle90. 
Mechanisms underlying the possible relationship between contraceptives and HIV risk 
Impact of long-acting contraceptives on FGT immunity 
Progestins exert their function by interacting with a variety of steroid receptors and thereby 
altering downstream gene expression. The most important receptor in this context is the 
progesterone receptor (PR), however, progestins also interact with the glucocorticoid receptor 
(GR), as well as the mineralocorticoid receptor (MR), among others91. Although progestins are 
generally designed to act like progesterone, different progestins interact with members of the 
steroid receptor family to varying degrees and thus cause differential effects. Overall it is 
important to note that all progestins have a higher affinity for the PR in comparison to 
endogenous progesterone73,92. Interestingly, the progestin MPA seems to be an outlier with 
regards to steroid receptor binding. Unlike NET-EN and its endogenous counterpart 
progesterone, it has a high affinity for the GR. On the contrary, while progesterone has a high 
affinity for the MR, MPA has a low affinity73,93. Although these relationships have been 
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established, the downstream effects of this differential binding are largely unknown. It is also 
important to note that the affinity of an analyte is not necessarily directly proportional to 
biological activity, however, as MPA is a clear outlier in this regard, it is worth investigating 
further. 
It is well documented that high doses of MPA (approx. 1000 mg/day) have immunosuppressive 
effects and are frequently used to treat cancer patients undergoing therapy94. Although these 
effects have been observed in previous studies, the cut-off concentration, below which 
immunosuppression is possibly no longer observed, as well as its application to immunity in 
the FGT, remains unknown. In line with the possibility of immunosuppressive properties, 
Ngcapu, et al. reported that the FGTs of women using injectables had an overall less 
inflammatory profile than women not using injectables95. 
Contrary to these findings, numerous studies describing the inflammatory potential of the 
hormone progestin and its synthetic analogues have emerged, specifically with regards to the 
FGT. Calla et al. recently demonstrated that DMPA, as well as LNG, usage was associated 
with tissue inflammation in the FGT. The authors established a model whereby decreased 
levels of the desmosomal cadherin desmoglein-1a lead to increased mucosal permeability and 
thus facilitated the invasion of endogenous vaginal bacteria, increasing genital inflammation 
overall96. Furthermore, it has been demonstrated that cervical cells obtained from women using 
DMPA contained higher numbers of activated HIV target cells.  On the contrary, women using 
IUDs as a method of contraception had reduced expression of the CCR5 co-receptor on CD4+ 
T cells in cervical cells97. Morrison et al. showed that DMPA users had higher levels of 




The possible biological link between long-acting contraceptives and HIV risk is thus likely 
multifactorial, with increased or decreased genital inflammation playing a central role. 
Furthermore, if there are concentration ranges which determine whether the effects of DMPA 
are anti- or pro-inflammatory, these are unknown and should be investigated. The uncertainty 
around the effects of DMPA on FGT immunity is further highlighted in a recent study by 
Zalenskaya et al. in which the authors assessed the effects of DMPA on gene expression in 
ectocervical tissues. Pathway analyses demonstrated that predicted alterations of the 
transcriptome correlated with an immunosuppressive effect of DMPA, however, in some 
women they were more compatible with an inflammatory-like response98.  
A recent study reported that NET-EN use was not linked to an increase in FGT cytokine levels 
when compared to combined contraceptive vaginal rings99. Contrary to this, Dabee et al. 
detected an upregulation of 33/44 genital cytokines in women using DMPA-IM, as well as 
NET-EN100. Another study has linked NET-EN use to increased levels of IL-6, IL-8 and 
RANTES concentrations in the FGT101. It becomes clear that studies assessing genital 
inflammation following the use of NET-EN and DMPA-IM have produced diverse results and 
more research is needed to determine how injectables may influence HIV acquisition risk.  
Impact of contraceptives on cervicovaginal structure 
Early evidence for the possible association between progesterone and HIV emerged from 
studies in non-human primates that showed that implants containing 200 mg of progesterone 
increased the susceptibility to SIV infection following vaginal inoculation102. Furthermore, 
MPA has been administered intramuscularly in doses comparable to those given to women for 
contraceptive purposes to facilitate infection with STIs in mouse and non-human primate 
models103. Thinning of the vaginal epithelium was proposed as the potential underlying 
mechanism102. In primate models, this is commonly observed in response to high doses of 
progesterone (i.e. during the luteal phase of the menstrual cycle as discussed earlier67) or its 
synthetic analogue progestin, as found in the contraceptive DMPA102. Whether these changes 
can be directly translated to humans is currently less clear and debated among scientists104,105. 
Zalenskaya et al., supported this theory in a study that assessed differences in gene expression 
in ectocervical tissues between women using DMPA and COCs. The expression of 235 genes 
was significantly altered and mostly downregulated in response to DMPA usage, with the 
majority involved in maintenance of mucosal barrier integrity98.  
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Impact of synthetic hormones on endogenous hormones 
While most reports focus exclusively on the effects of progesterone and its synthetic analogue 
on HIV risk, Villegas, et al., recently investigated the importance of oestradiol in the protection 
against HIV infection59. Most importantly, an inverse relationship between serum 
concentrations of oestradiol and efficiency of HIV infection of endo- and ectocervical tissue 
ex vivo was established. This suggests that, contrary to progesterone and its analogues, 
oestradiol plays a protective role in the context of HIV infection. Different forms of HC may 
have different effects on endogenous levels of oestradiol. A comparison of serum oestradiol 
levels for different forms of HCs has revealed that DMPA-IM users are typically in a 
hypoestrogenic state105. Hypoestrogenism may reportedly have effects on epithelial integrity, 
the FGT microbiota and immune function in the FGT as a whole and may thus be crucial in the 
context of HIV risk106. It is important to note that DMPA-IM is a progestin-only contraceptive 
and, unlike some other HCs, such as most COCs, contains no synthetic analogue of oestrogen.  
HCs and the acquisition of STIs and BV 
The immunosuppressive properties of high DMPA doses are thought to leave the FGT 
vulnerable to infection with genital pathogens, including BV and STIs other than HIV. 
However, the evidence for potential associations between the use of HCs and risk of STIs aside 
from HIV is sparse, with few studies investigating further. STIs have been identified as a major 
cause of elevated cytokine concentrations in the FGT36, increased HIV risk and increased risk 
of reproductive complications. Therefore, the impact of long-acting HCs on the risk of STI 
acquisition has important public health implications.  
Two studies have recently suggested a link between oral contraceptive use and chlamydia 
infections but not other STIs, including gonorrhoea, HSV-2, trichomoniasis, syphilis, and 
human papillomavirus (HPV)83,107. Interestingly, COC use was also associated with the 
development of cervical ectopy, which in turn increases the risk of chlamydia, HPV, as well as 
HIV infection73. Additionally, studies in mice have shown a 2-fold increase in HSV-2 infection 
when treated with DMPA108.  
Information on the effects of DMPA-IM on the vaginal microbiome is limited and studies have 
reported highly inconsistent results. Cultivation-based longitudinal studies have shown a 
decrease in H2O2-producing Lactobacillus spp., both 6 and 12 months after initiation of DMPA 
use. In line with this, low oestrogen levels that are associated with the use of progestin-only 
contraceptives correlated with decreased growth of Lactobacillus spp. and increased growth of 
BV-associated bacteria in the FGT109. Meanwhile, the use of HCs that are formulated with 
21 
 
oestrogen has been linked to a decrease in BV-associated bacteria in the FGT109. Oestrogen 
induces the accumulation of glycogen in the vaginal epithelium and it is thus thought that 
synthetic oestrogen-containing contraceptives positively influence colonization by 
Lactobacillus spp. (that utilise glycogen as a food source) and therefore confer protection from 
BV110. 
Contrary to the results described above, Roxby et al. observed a decrease in G. vaginalis growth 
alongside an increase in L. crispatus numbers following DMPA-IM initiation 111. However, a 
study with a similar design observed a decrease in L. iners growth but no effect on more 
beneficial Lactobacillus strains110. Additionally, it has been suggested that the effects observed 
in response to DMPA are dependent on the ethnicity of the user. Yang et al. demonstrated that 
while black women showed an increased colonization of BV-associated bacteria in their FGTs, 
the same was not observed in Hispanic and white women following the use of the HC112.  
Additionally, there are conflicting results regarding current data evaluating the risk of 
acquisition of STIs other than HIV in IUD users. For example, while some studies reported an 
increase in risk of C. trachomatis infection in current IUD users113, others failed to establish 
this link114. Interestingly, it has been suggested that the copper IUD can affect the vaginal 
microbiome. A recent study demonstrated that the prevalence of BV in a cohort of copper IUD 
users increased from 27% at baseline to 35% at 30 days and reached 49% at 180 days following 
initiation110. Specifically, two key BV-associated bacterial spp., G. vaginalis and A. vaginae, 
showed an increase in growth. Similarly, Brooks et al. found a number of taxa typically 
associated with a dysbiotic vaginal microbiome, including Prevotella spp., Sneathia amnii and 
Megasphaera spp., to be significantly more abundant in women using the LNG-intrauterine 
system (IUS), more commonly known as the Mirena109. The results linking IUDs/IUSs to a 
higher risk of developing vaginal dysbiosis could have important public health implications 
with regards to HIV risk in IUD users and further investigations are crucial. 
Studies assessing the risk of the acquisition of other STIs in implant users are somewhat more 
available but also limited. Studies by Maucort-Boulch et al. and McClelland et al. reported a 
lack of association between use of the LNG implant and HPV persistence as well as BV, 
respectively115,116. On the contrary, a study of a Ugandan cohort found that LNG implant use 
was associated with higher rates of trichomonas infection when compared to women not using 
any form of HC117. Furthermore, a study conducted in sub-Saharan Africa linked the use of 
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LNG implants to a higher risk of gonorrhoea, but not syphilis85. Overall these results are 
inconclusive and largely based on observational studies. 
Rationale 
Cytokine profiles in the FGT are thought to play an important role in the HIV risk of 
individuals. The effects of HCs on these cytokine profiles (and by extension HIV risk) requires 
further attention as part of the investigation into biological mechanisms that facilitate the 
disproportionally high burden of HIV infections in women. Additionally, aside from the 
question of altered HIV risk, it remains unknown whether certain contraceptives cause vaginal 
microbiome and immune changes that may influence reproductive health. 
Aims 
1. To investigate changes in cytokine signatures associated with the initiation of DMPA-
IM and compare these to LNG implant and copper IUD insertion. 
2. To evaluate baseline demographic and biological factors that may alter cytokine 




Methods and Materials 
Study participants 
The impact of two progestins (MPA and LNG) and the copper IUD on the cytokine signatures 
in the FGT tract were evaluated in this study. FHI 360 collected specimens as part of the ECHO 
(Evidence for Contraceptive Options and HIV Outcome) study78. ECHO was a randomized 
controlled trial to evaluate the HIV incidence among 7800 women randomized to 150 mg 
intramuscular DMPA, the LNG implant or the copper IUD in South Africa, Kenya, Zambia 
and Swaziland. The samples included in the present study were collected at two sites in South 
Africa, Setshaba Research Centre (SRC) in Pretoria (n=54) and MatCH Research Unit (MRU) 
in Durban (n=113). Specimens were collected at baseline, i.e. immediately prior to method 
initiation, month 1 (M1) and month 3 (M3) in order to facilitate immune assessment at near 
peak and near trough MPA concentrations. Demographic and behavioural data were collected 
by questionnaire. 
Specimen collection 
Lateral vaginal wall swabs were collected at each visit for measurement of cytokines and 
secretory leukocyte protease inhibitor (SLPI) concentrations. Dacron swab samples were 
collected by placing the swabs on the lateral vaginal wall and rotating 360 degrees. Swabs were 
placed in cryovials and stored at -80C. All collected samples were kept at 4⁰C immediately 
after collection and transported to the clinic laboratory for storage within 4 hours of collection.   
STI diagnosis 
STI diagnosis was conducted at Bio Analytical Research Corporation South Africa (BARC 
SA) and included detection of Chlamydia trachomatis and Neisseria gonorrhoeae using 
GeneXpert and herpes simplex virus type 2 serology78.  
Lateral vaginal wall swab processing and aliquoting  
The frozen lateral vaginal wall swabs were thawed on ice overnight at 4⁰C. The following day, 
1 mL of phosphate buffered saline (PBS; Sigma-Aldrich, P5493) was added to each tube 
containing a swab. The tubes were vortexed for 60 sec at a low speed and subsequently 
incubated at 4⁰C for 1 hour. Holding the swab, excess mucus was scraped off on the wall of 
the tubes and each tube was vortexed for 30 sec at a low speed. The supernatants were 
transferred into filter centrifuge tubes (Corning® Costar® Spin-X® tubes Sigma-Aldrich, 
CLS8160) and centrifuged for 10 min at top speed (4000 rpm). Filters were removed and the 
supernatants vortexed for 10 sec at a low speed prior to cytokine/SLPI measurement. The tubes 
were kept on dry ice throughout this protocol.  
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Cytokine, antimicrobial peptide and prostate specific antigen measurement 
Using lateral vaginal wall swabs collected as part of the ECHO trial, pro-inflammatory 
cytokines and chemokines including MIP-1α, MIP-1β, MIP-3α, IP-10, RANTES, IL-6, IL-8, 
IL-1β and TNF-α, innate immune mediator IFN-α and antimicrobial peptide SLPI were 
measured using Human Magnetic Luminex Screening Assays (R&D Systems, Minneapolis, 
USA. Lot L128368; supplementary figure S1). The assay principle is explained in detail in the 
appendix (figure S1). Samples were analysed on a Bio-Rad Bio-Plex® 200 system with Bio-
Plex Manager Software 6.1 (Bio-Rad, Hercules, CA) as described previously4. Cytokines were 
measured in duplicate and the averages of the duplicates were used for downstream analysis. 
Samples were run over 13 plates for each, the larger panel (MIP-1α, MIP-3α, IP-10, IL-6, IL-
8, IL-1β, TNF-α, IFN-α and SLPI) and the smaller panel of cytokines (MIP-1β and RANTES). 
Examples of standard curves for each immune mediator are shown in the Appendix (figure S2). 
Prostate specific antigen (PSA) was measured by Mr Rushil Harryparsad using Human 
Kallikrein 3/PSA Quantikine ELISA (R&D Systems, US) to determine the presence of semen 
contamination. 
Data analysis 
Differences in median cytokine concentrations were assessed based on baseline demographic 
data, namely site, age group, body mass index (BMI), Chlamydia trachomatis status, Neisseria 
gonorrhoeae status, HSV-2 status as well as PSA presence/absence (using Mann-Whitney U 
test, Kruskal-Wallis test and Fisher’s Exact test; GraphPad Prism). Changes in cytokine 
concentrations among the different contraceptive methods were assessed using Wilcoxon 
signed rank test at one- and three-months post contraceptive initiation. Differences in fold 
changes in cytokine concentrations between the contraceptive methods at one- and three-
months post contraceptive initiation were assessed using Mann-Whitney U test. P-values were 
adjusted for multiple comparisons using a false discovery step down procedure. Principal 
component analysis (PCA) was used to group pro-inflammatory cytokines (TNF-α, IL-6 and 
IL-1β) and chemokines (IL-8, MIP-1α, IP-10, MIP-3α, MIP-1β and RANTES) and to generate 
estimates for each group. Differences in the magnitude of change of these PCA estimates 
between the contraceptive methods were assessed using Mann-Whitney U test. Additionally, 
PCA was performed on log10-transformed fold change values of immune mediator 
concentrations at one- and three-months following initiation of contraceptive method using the 
mixOmics package in R (R Foundation for Statistical Computing, Vienna, Austria). Heat maps 
of the log10-transformed fold changes in immune mediator concentrations were generated using 
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R. Mixed effects linear regression analysis using the log10-transformed immune mediator 
concentrations was used to assess changes over time (STATATM, StataCorp). Multinomial 
logistic regression analysis using the log10-transformed fold change data was used to assess the 
effects of possible confounders, namely site and age as well as gonorrhoea, chlamydia and 
HSV-2 status on immune mediator concentrations (STATATM).  
Results 
Baseline Demographics 
The concentrations of eleven immune mediators were measured in lateral vaginal wall swabs 
from 167 women randomised to the injectable DMPA-IM (n=53), the copper IUD (n=55) or 
the LNG Implant (n=59). The relationships between baseline demographic data and immune 
mediator concentrations were evaluated to identify potential confounders (table 1). 
Concentrations of the pro-inflammatory cytokine IL-6 and the chemokine MIP-3α were 
significantly higher in women from SRC when compared to those from MRU. No significant 
differences in STI prevalence across the two sites was detected (figure 1). While PSA levels, 
as a biomarker of recent unprotected sexual intercourse, were significantly higher in women 
from MRU at baseline visit, women from SRC showed higher concentrations of the protein at 
both follow-up visits (figure 2). Women in the age groups of 18-20 and 21-24 years tended to 
have elevated concentrations of TNF-α, IL-1β, IL-8, MIP-1α, IP-10, SLPI and MIP-1β when 
compared to the ages 25-30 and 31-35 years. This trend was statistically significant for the pro-
inflammatory IL-1β and the chemokines IL-8 and MIP-1α after adjusting for multiple 
comparisons. No significant differences in age were found between the two sites (figure S9). 
Immune mediator concentrations were generally higher in women with a BMI ≤ 30 compared 
to those with a BMI > 30, however statistical significance was not observed. All immune 
mediators, with the exception of MIP-1β, were present at lower concentrations in HSV-2 
seropositive women but this trend was only statistically significant for the chemokine MIP-1α 
after adjusting for multiple comparisons. Infection with C. trachomatis had a diverse effect on 
immune mediator concentrations with some, including IL-1β, IL-8, MIP-1α, IP-10 and MIP-
1β slightly raised in women who tested positive for the pathogen. Others, namely TNF-α, IL-
6, MIP-3α, IFN-α and SLPI, were detected at lower levels in infected women, however, none 
of these associations remained significant after adjusting for multiple comparisons. Levels of 
immune mediators were generally higher in women infected with N. gonorrhoeae, particularly, 
IL-6 and IL-8 but this trend was not statistically significant after adjusting for multiple 
comparisons. The presence of PSA was not associated with any significant trends in immune 
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mediator concentrations, but levels of IL-6 and MIP-3α were slightly raised in the presence of 
















median (range) p value median (range) p value median (range) p value 
Site: Setshaba 
Commercial City (n=54) 
16.66 (86.29) 0.0352 14.19 (336.7) 0.0028* 30.49 (4027) 0.3725 








       
 
median (range) p value median (range) p value median (range) p value 
18-20 (n=33) 16.06 (70.89) 0.2175 10.48 (69.85) 0.1204 50.13 (4024) 0.0032* 


















       
BMI median (range) p value median (range) p value median (range) p value 
≤ 30 (n=30) 15.95 (86.29) 0.0632 11.41 (340.3) 0.1898 31.85 (2386) 0.2035 






       
HSV-2 median (range) p value median (range) p value median (range) p value 
Indeterminate (n=18) 11.19 (37.17) 0.0557 10.06 (67.24) 0.0822 26.63 (4026) 0.1153 












       
Chlamydia trachomatis median (range) p value median (range) p value median (range) p value 
Negative (n=125) 15.95 (86.29) 0.0943 11.28 (173.3) 0.8752 29.21 (4027) 0.1780 






       
Neisseria gonorrhoeae median (range) p value median (range) p value median (range) p value 
Negative (n=160) 14.44 (86.29) 0.7267 10.76 (430.7) 0.0234 30.51 (4027) 0.1166 






       
PSA median (range) p value median (range) p value median (range) p value 
Negative (n=148) 15.62 (86.29) 0.3203 10.58 (340.3) 0.5473 31.6 (2386) 0.7141 













 MIP-1α  
(n=167) 




median (range) p value median (range) p value median (range) p value 
Site: Setshaba 
Commercial City (n=54) 
397.8 (29305) 0.9993 184.8 (854.1) 0.4986 15.08 (3924) 0.5120 
Site: MatCH Research 
Centre (n=113) 
469.8 (29310)  180.1 (718)  12.14 (3924)  
 
       
median (range) p value median (range) p value median (range) p value 
18-20 (n=33) 867.2 (29305) 0.0075* 229.9 (569.9) 0.0008* 25.74 (78.39) 0.0515 
21-24 (n=72) 522.7 (29310)  206.6 (854.1)  15.15 (3924)  
25-30 (n=43) 235.2 (29296)  110.8 (460.6)  8.91 (3924)  
31-35 (n=19) 329.4 (3048)  150.2 (590.5)  4.74 (197)  
 
      
BMI median (range) p value median (range) p value median (range) p value 
≤ 30 (n=30) 536.7 (29309) 0.2034 206.3 (854.1) 0.0072 16.09 (317) 0.1258 
> 30 (n=54) 244.0 (29310)  153.6 (576.9)  10.58 (3924)  
 
      
HSV-2 median (range) p value median (range) p value median (range) p value 
Indeterminate (n=18) 954.5 (29310) 0.0185 202.8 (359.6) 0.0016* 14.55 (94.8) 0.1748 
Negative (n=91) 535.4 (29305)  206.3 (759.7)  16.02 (3924)  
Positive (n=56) 208 (29298)  139.1 (854.1)  8.565 (3924)  
 
      
Chlamydia Trachomatis median (range) p value median (range) p value median (range) p value 
Negative (n=125) 407.6 (29310) 0.4372 181.9 (854.1) 0.405 13.94 (3924) 0.3264 
Positive (n=42) 615.9 (29309)  184.5 (718)  15.02 (120.9)  
 
      
Neisseria gonorrhoeae median (range) p value median (range) p value median (range) p value 
Negative (n=160) 422.8 (29310) 0.0523 182.3 (854.1) 0.1998 13.91 (3924) 0.4529 
Positive (n=7) 1120 (29219)  193.2 (205.8)  16.84 (93.29)  
 
      
PSA median (range) p value median (range) p value median (range) p value 
Negative (n=148) 451.7 (29310) 0.5423 184.1 (854.1) 0.7972 14.14 (3924) 0.6427 








 IFN-α  
(n=167) 




median (range) p value median (range) p value median (range) p value 
Site: Setshaba 
Commercial City (n=54) 
28.04 (255) 0.0026* 23.66 (91.54) 0.1426 70685 (1411682) 0.0375 
Site: MatCH Research 
Centre (n=113) 
14.31 (117.4)  20.11 (60.73)  34848 (1413049)  
 
       
median (range) p value median (range) p value median (range) p value 
18-20 (n=33) 23.72 (167.5) 0.4585 22.85 (53.44) 0.2465 44315 (1411313) 0.4096 
21-24 (n=72) 23.22 (255)  20.90 (93.88)  65913 (1413013)  
25-30 (n=43) 10.30 (124.1)  16.54 (39.12)  39695 (621985)  
31-35 (n=19) 11.90 (81.26)  23.37 (51.88)  32844 (714834)  
 
      
BMI median (range) p value median (range) p value median (range) p value 
≤ 30 (n=30) 22.27 (255) 0.4214 21.59 (93.88) 0.1314 63757 (1413013) 0.1241 
> 30 (n=54) 13.14 (90.11)  18.43 (55.22)  28388 (714834)  
 
      
HSV-2 median (range) p value median (range) p value median (range) p value 
Indeterminate (n=18) 29.18 (106.9) 0.1418 18.52 (73.81) 0.1 24445 (622125) 0.2637 
Negative (n=91) 22.27 (255)  21.65 (62.98)  63663 (1413013)  
Positive (n=56) 11.17 (124.1)  18.03 (96.78)  29465 (1413049)  
 
      
Chlamydia Trachomatis median (range) p value median (range) p value median (range) p value 
Negative (n=125) 19.21 (255) 0.8241 21.03 (96.78) 0.5338 55652 (1413049) 0.1296 
Positive (n=42) 14.98 (106.9)  18.42 (45.95)  31322 (1411209)  
 
      
Neisseria gonorrhoeae median (range) p value median (range) p value median (range) p value 
Negative (n=160) 17.55 (255) 0.2386 20.48 (96.78) 0.7206 45657 (1413049) 0.5329 
Positive (n=7) 30.31 (106.9)  21.05 (43.77)  73094 (241809)  
 
      
PSA median (range) p value median (range) p value median (range) p value 
Negative (n=148) 15.21 (255) 0.2658 20.9 (96.78) 0.2595 54996 (1413049) 0.4825 

























Abbreviations: BMI, body mass index; HSV, herpes simplex virus type 2; PSA, prostate specific antigen; TNF-
α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ 
inducible protein-10; IFN-α, interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated 
on activation, normal T cell expressed and secreted. *Indicates p < 0.05 by Mann Whitney U/Kruskal Wallis test 









median (range) p value median (range)  
Site: Setshaba 
Commercial City (n=54) 
226.5 (946.6) 0.7307 3.485 (419.5) 0.0141 
Site: MatCH Research 
Centre (n=113) 
122.6 (1114)  3.485 (609.4)  
 
     
median (range) p value median (range)  
18-20 (n=33) 292.2 (946.6) 0.3056 3.485 (291) 0.3415 
21-24 (n=72) 177.7 (1114)  3.485 (609.4)  
25-30 (n=43) 39.66 (886.5)  3.485 (270.7)  
31-35 (n=19) 39.66 (451.6)  3.485 (82.45)  
 
    
BMI median (range) p value median (range) p value 
≤ 30 (n=30) 177.7 (1114) 0.4520 3.485 (609.4) 0.6803 
> 30 (n=54) 39.66 (979.5)  3.485 (419.5)  
 
    
HSV-2 median (range) p value median (range) p value 
Indeterminate (n=18) 239.9 (946.6) 0.2029 3.485 (609.4) 0.0178 
Negative (n=91) 204.2 (1114)  3.485 (419.5)  
Positive (n=56) 39.66 (26.4)  3.485 (250.1)  
 
    
Chlamydia Trachomatis median (range) p value median (range) p value 
Negative (n=125) 79.31 (1114) 0.2209 3.485 (270.7) 0.3218 
Positive (n=42) 251 (946.6)  3.485 (609.4)  
 
    
Neisseria gonorrhoeae median (range) p value median (range) p value 
Negative (n=160) 165.2 (1114) 0.8045 3.485 (609.4) 0.4793 
Positive (n=7) 39.66 (946.6)  3.485 (419.5)  
 
    
PSA median (range) p value median (range) p value 
Negative (n=148) 177.7 (1114) 0.3106 3.485 (609.4) 0.6235 
Positive (n=19) 39.66 (520.5)  3.485 (204.7)  
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Figure 1. Sexually transmitted infection (STI) prevalence (%) across sites.  Women from 
Setshaba Research Centre (n=55; blue) and MatCH Research unit (n=113; pink) were tested for the presence of 
HSV-2 antibodies in blood, and N. gonorrhoea and C. trachomatis in endocervical swabs using GeneXpert. 
Fisher’s exact test was used for comparisons. Abbreviations: HSV-2, herpes simplex virus type 2.  
 
Figure 2. Prostate specific antigen (PSA) concentrations across sites. PSA levels were 
measured in lateral vaginal wall swab samples using ELISA. Mann Whitney U test was used to compare PSA 
concentrations between women from Setshaba Research Centre (n=55; blue) and MatCH Research Unit (n-113; 
pink). Abbreviations: PSA, Prostate specific antigen. P-values <0.05 were considered statistically significant. 
Setshaba Research Centre  
MatCH Research Unit  
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Immune mediator detection 
Generally, strong positive correlations were observed between duplicate immune mediator 
measurements (figure 3 A-K). Spearman’s correlation coefficient between duplicate cytokine 
concentration readings was generally high, with all correlation coefficients >0.87, with the 
exception of MIP-1β (0.72). The percentage of samples with undetectable cytokine/SLPI 
concentrations ranged from <1 to 27% for most immune mediators (table 2, figure 4). The 
exceptions were MIP-1β and RANTES, which were undetectable in 42% and 73% of samples, 
respectively.  
Figure 3 (A-K). Correlations between duplicate immune mediator concentrations (pg/mL). Genital immune 
mediator concentrations in lateral vaginal wall swabs were measured in duplicate using Luminex and duplicate 
values were plotted against each other in the scatter plots. Abbreviations: TNF-α, tumour necrosis factor-alpha; 
IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, 
Interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell 







p value  % Undetected 
TNF-α 0.9665 <0.0001 0.034205231 
IL-6 0.9334 <0.0001 0.004024145 
IL-1β 0.9653 <0.0001 0.026156942 
IL-8 0.9530 <0.0001 0.054325956 
MIP-1α 0.9647 <0.0001 0.175050302 
IP-10 0.9489 <0.0001 0.076458753 
MIP-3α 0.8741 <0.0001 0.269617706 
IFN-α 0.9303 <0.0001 0.008048290 
SLPI 0.9761 <0.0001 0.028169014 
MIP-1β 0.7246 <0.0001 0.416498994 
RANTES 0.9141 <0.0001 0.730382294 
Figure 4. Percentage of samples with undetectable immune mediator concentrations. Genital 
immune mediator concentrations in lateral vaginal wall swabs were measured in duplicate using 
Luminex and the proportion of undetectable concentrations per immune mediator was determined. 
Abbreviations: TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory 
protein; IP-10, interferon-γ inducible protein-10; IFN-α, Interferon-alpha, SLPI, secretory leukocyte 
protease inhibitor; RANTES, regulated on activation, normal T cell expressed and secreted. 
Table 2. Correlation analysis of duplicate measurements per 
immune mediator.  
Abbreviations: TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, 
macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; 
IFN-α, Interferon-alpha, SLPI, secretory leukocyte protease inhibitor; 
RANTES, regulated on activation, normal T cell expressed and secreted. 
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Analysis of absolute immune mediator concentrations 
The copper IUD was associated with rapid increases in inflammatory markers following 
contraceptive initiation. Pro-inflammatory IL-6 (figure 5B) and IL-1β (figure 5C) and 
chemotactic IL-8 (figure 5D), MIP-1⍺ (figure 5E), IP-10 (figure 5F), and MIP-1β (figure 5J) 
were significantly elevated one month following copper IUD insertion after adjusting for 
multiple comparisons. While RANTES was significantly elevated one-month following copper 
IUD insertion, this did not remain significant after adjusting for multiple comparisons (figure 
5K). Concentrations of the pro-inflammatory IL-6 and chemotactic IP-10 remained 
significantly raised compared to baseline after three months of contraceptive use, although to 
a lesser extent when compared to month one and were not significant after adjusting for 
multiple comparisons. A slight decrease was observed in SLPI concentrations (figure 5I) one 
month post contraceptive initiation, however this was not statistically significant and 
concentrations of this protein at three months following contraceptive initiation were 
comparable to baseline. Insertion of copper IUD was not associated with changes in 
concentrations of TNF-α (figure 4A) and IFN-α (figure 5H).  
Initiation of DMPA-IM was not associated with any significant changes in immune mediator 
concentrations. One-month following contraceptive initiation, slight decreases in TNF-α 
(figure 6A) and SLPI (figure 6I) concentrations were observed, however these changes were 
not significant. While concentrations of IFN-α (figure 6H) decreased three months after 
contraceptive initiation, this change was not statistically significant after adjusting for multiple 
comparisons.  
No changes in immune mediator concentrations were evident one-month post LNG insertion, 
but at three months, concentrations of TNF-⍺ (figure 7A), IP-10 (figure 7E), MIP-3⍺ (figure 
7G) and SLPI (figure 7I) were significantly raised relative to baseline. Concentrations of the 
chemokine IL-8 (figure 7D) were elevated at three months post contraceptive initiation but this 
association was not significant after adjusting for multiple comparisons. 
Line graphs of this analysis visualizing changes in immune mediator concentrations in 
individual women are shown in the appendix (figure S3-S5). A contingency analysis revealed 






Figure 5 (A-K). Genital immune mediator concentrations (pg/mL) at baseline, one month following 
insertion of copper IUD (m1) and three months (m3) following insertion of copper IUD (n=55). Genital 
immune mediator concentrations in lateral vaginal wall swabs were measured using Luminex. Wilcoxon signed 
rank test was used for comparisons and p-values were adjusted for multiple comparisons using a false discovery 
rate step-down procedure. Abbreviations: m1, one-month post copper IUD insertion; m3, three months post 
copper IUD insertion; TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory 
protein; IP-10, interferon-γ inducible protein-10; IFN-α, interferon-alpha, SLPI, secretory leukocyte protease 
inhibitor; RANTES, regulated on activation, normal T cell expressed and secreted. * Indicates p < 0.05 after 




Figure 6 (A-K). Genital immune mediator concentrations (pg/mL) at baseline, one month following 
initiation of DMPA-IM (m1) and three months (m3) following initiation of DMPA-IM (n=53). Genital 
immune mediator concentrations in lateral vaginal wall swabs were measured using Luminex. Wilcoxon signed 
rank test was used for comparisons and p-values were adjusted for multiple comparisons using a false discovery 
rate step-down procedure. Abbreviations: m1, one-month post DMPA-IM initiation; m3, three months post 
DMPA-IM initiation;  TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory 
protein; IP-10, interferon-γ inducible protein-10; IFN-α, Interferon-alpha, SLPI, secretory leukocyte protease 
inhibitor; RANTES, regulated on activation, normal T cell expressed and secreted. * Indicates p < 0.05 after 




Figure 7 (A-K). Genital immune mediator concentrations (pg/mL) at baseline, one month following 
insertion of LNG Implant (m1) and three months (m3) following insertion of LNG Implant (n=59). Genital 
immune mediator concentrations in lateral vaginal wall swabs were measured using Luminex. Wilcoxon signed 
rank test was used for comparisons and p-values were adjusted for multiple comparisons using a false discovery 
rate step-down procedure. Abbreviations: m1, one-month post LNG insertion; m3, three months post LNG 
insertion; Cu-IUD, Copper intrauterine device; TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, 
macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, interferon-alpha, SLPI, 
secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell expressed and secreted. 





Figure 8. Contingency analysis of MIP-1β (A) and RANTES (B) by contraceptive arm. Genital immune 
mediator concentrations in lateral vaginal wall swabs were measured in duplicate at baseline. The concentrations 
for these two cytokines were grouped by arm, namely copper IUD (n=52), DMPA-IM (n=50) and LNG implant 
users (n=56) and categorized into detectable (blue) and undetectable (pink) concentrations. Fisher’s exact test was 
used for comparisons. Abbreviations: Cu-IUD, copper intrauterine device; DMPA-IM, depomedroxyprogesterone 
acetate; LNG, levonorgestrel; MIP, macrophage inflammatory protein, RANTES, regulated on activation, normal 




Analysis of fold change in immune mediator concentrations 
Fold changes (FC) in immune mediator concentrations were compared between the different 
contraceptive methods at one- and three-months following contraceptive initiation. One month 
post contraceptive initiation, fold change values were generally higher in copper IUD users 
when compared to DMPA-IM and the LNG implant. Increases in the concentrations of the pro-
inflammatory cytokines TNF-α (1.2-fold, figure 9A), IL-6 (1.5-fold, figure 9B), IL-1β (1.8-
fold, figure 9C), the chemokines IL-8 (1.4-fold, figure 9D), MIP-1α (1.2-fold, figure 9E), IP-
10 (1.6-fold, figure 9F), MIP-3α (1.5-fold, figure 9G), SLPI (1.2-fold, figure 9I) as well as 
MIP-1β (1.3-fold, figure 9K) were observed. After adjusting for multiple comparisons this 
trend was statistically significantly higher for the chemokine MIP-1β (figure 9K) and the 
cytokine IL-1β (figure 9C) in the copper IUD arm when compared to the other contraceptive 
methods and the LNG implant, respectively. Slight to no changes in immune mediator 
concentrations were evident one-month post contraceptive initiation in DMPA-IM and LNG 
implant users, with the exception of a greater increases in concentrations of IL-1β (1.2-fold) in 
DMPA-IM users compared to women using the LNG implant (figure 9C) after adjusting for 
multiple comparisons. A non-significant 1.4-fold increase in IP-10 concentrations in LNG 
implant users was also observed (figure 9F). Additionally, with a fold change value below one, 
concentrations of TNF-α (0.9-fold, figure 9A) and SLPI (0.7-fold, figure 9I) were decreased in 
DMPA-IM users one month following injection with the contraceptive relative to baseline. No 
changes in RANTES (figure 9J) levels were evident one month post contraceptive initiation.  
Three months following contraceptive initiation, concentrations of IL-8 (1.2- and 1.4-fold, 
figure 10D), MIP-1α (1.1- and 1.3-fold, figure 10E), IP-10 (1.5- and 1.6-fold, figure 10F), MIP-
3α (1.2- and 1.2-fold, figure 10G) and SLPI (1.2- and 1.8-fold, figure 10I) were changed in 
women using both, the copper IUD and LNG implant, respectively. Compared to DMPA-IM 
users this change was significant for IL-6 in copper IUD users after adjusting for multiple 
comparisons. Of the two contraceptive methods, LNG implant insertion was generally 
associated with higher fold changes in these immune mediators at three months. Use of the 
implant was additionally associated with a 1.3-fold increase in TNF-α levels three months post 
contraceptive initiation that was significant compared to the DMPA-IM arm, but fell away after 
adjusting for multiple comparisons (figure 10A). A 1.9- and 1.6-fold change in IL-1β (figure 
10C) and IL-6 (figure 10B), respectively, were observed at three months following copper IUD 
insertion, with the latter remaining significant compared to women using DMPA-IM after 
adjusting for multiple comparisons. While levels of IFN-α were lower three-months post 
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DMPA-IM injection (0.9-fold, figure 10H) relative to baseline, concentrations of IL-8 (figure 
10D) and SLPI (figure 10I) were slightly elevated with 1.1- and 1.3-fold increases, 
respectively. However none of these changes were significant in the DMPA-IM arm compared 
to the copper IUD or LNG arms. No changes in RANTES (figure 10J) and MIP-1β (figure 
10K) levels were evident three months post contraceptive initiation.  
The cumulative median fold changes for all immune mediators were used to summarise and 
assess overall changes in genital cytokine profiles for each contraceptive method at one- and 
three-months post initiation (figure 11). Levels of immune mediators were raised in copper 
IUD users both one- (cumulative FC: 14.8) and three-months (cumulative FC: 13.8) following 
insertion. Additionally, LNG implant use was associated with an overall increase in genital 
immune mediator levels three months following insertion (cumulative FC: 13.8). No overall 
changes in cytokine profiles were observed in DMPA-IM users, with cumulative fold changes 















Figure 9 (A-K). Fold changes in genital immune mediator concentrations one month following initiation of 
copper IUD (n=52), DMPA-IM (n=50) or LNG implant (n=56) contraceptives. Genital immune mediator 
concentrations in lateral vaginal wall swabs were measured using Luminex. Mann-Whitney U test was used for 
comparisons and p-values were adjusted for multiple comparisons using a false discovery rate step-down 
procedure. Abbreviations: Cu-IUD, Copper intrauterine device; DMPA-IM, intramuscular 
depomedroxyprogesterone acetate; LNG, levonorgestrel; TNF-α, tumour necrosis factor-alpha; IL, interleukin; 
MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, interferon-alpha, SLPI, 
secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell expressed and secreted. 
* Indicates p < 0.05 after adjusting for multiple comparisons. The dotted lines indicate a 1-fold change, i.e. no 
change in immune mediator concentration.  
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Figure 10 (A-K). Fold change of genital immune mediator concentrations three months following initiation 
of copper IUD (n=55), DMPA-IM (n=53) and LNG implant (n=59) contraceptives. Genital immune mediator 
concentrations in lateral vaginal wall swabs were measured using Luminex. Mann-Whitney U test was used for 
comparisons and p values were adjusted for multiple comparisons using a false discovery rate step-down 
procedure. Abbreviations: Cu-IUD, Copper intrauterine device; DMPA-IM, intramuscular depo-
medroxyprogesterone acetate; LNG, levonorgestrel; TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, 
macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, interferon-alpha, SLPI, 
secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell expressed and secreted. 
* Indicates p < 0.05 after adjusting for multiple comparisons. The dotted lines indicate a 1-fold change, i.e. no 
change in immune mediator concentration. 
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Figure 11. Cumulative median fold change values of immune mediators per contraceptive method one- and 
three- months post copper IUD insertion (n=55), DMPA-IM initiation (n=53) and LNG implant insertion 
(n=59). Genital immune mediator concentrations in lateral vaginal wall swabs were measured using Luminex. 
Median fold change values for each cytokine were stacked to assess overall changes in genital cytokine profiles. 
Abbreviations: Cu-IUD, Copper intrauterine device; DMPA-IM, intramuscular depo-medroxyprogesterone 
acetate; LNG, levonorgestrel; m1, one month post contraceptive initiation; m3, 3 months post contraceptive 
initiation; TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, 
interferon-γ inducible protein-10; IFN-α, interferon-alpha, SLPI, secretory leukocyte protease inhibitor; 
RANTES, regulated on activation, normal T cell expressed and secreted. The dotted line indicates a cumulative 
11-fold change, i.e. no change in immune mediator concentrations. 
Principal component analysis 
PCA was used to group pro-inflammatory cytokines, chemokines and all cytokines to generate 
estimates for each group. The magnitude of change (MOC) of these estimates was assessed 
one- and three months following contraceptive initiation. Differences in pro-inflammatory, 
chemokine and overall cytokine profiles between the methods of contraception were assessed 
using Mann-Whitney U test. Of the eleven immune mediators analysed in this study, three are 
classified as pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) and six are classified as 
chemotactic cytokines (IL-8, MIP-1α, IP-10, MIP-3α, MIP-1β and RANTES). The immune 
mediator IFN-α was also considered for the overall profile group in this analysis.  
One-month post insertion, copper IUD use was associated with a significantly higher MOC in 
component estimates for pro-inflammatory cytokines (figure 12A), chemokines (figure 12B) 
as well as overall immune mediator profiles (figure 12C) when compared to DMPA-IM and 
LNG implant. While minimal changes in pro-inflammatory (figure 12A) as well as chemotactic 
44 
 
profiles (figure 12B) were observed at one month following DMPA-IM initiation, the trend 
was towards a decrease in pro-inflammatory cytokines, while chemokines tended to increase 
in concentration. The overall immune mediator profile tended to increase. LNG implant use 
was associated with a slight decrease in pro-inflammatory (figure 12A), as well as chemotactic 
cytokines (figure 12B), one month after contraceptive initiation. These changes were small but 
together resulted in a trend towards a decrease in overall immune mediator profile (figure 12C). 
Similar to one-month following contraceptive initiation, copper IUD use was associated with 
raised pro-inflammatory (figure 13A), chemotactic (figure 13B) as well as overall immune 
mediator profiles (figure 13C) three months following contraceptive initiation. This change 
was smaller in magnitude compared to one-month post copper IUD insertion, but was 
statistically significant for pro-inflammatory cytokine and overall cytokine profiles compared 
to the DMPA arm. While the trend was towards a slight increase in chemokine (figure 13B) 
concentrations at three months following DMPA-IM initiation, pro-inflammatory cytokines 
tended to decrease (figure 13A) and this trend persisted towards a reduction in overall immune 
mediator profiles (figure 13C). Pro-inflammatory cytokine profiles tended to increase three 
months post LNG implant insertion (figure 13A), and this was accompanied by an increase in 
chemotactic cytokine profiles (figure 13B). Together this resulted in a substantial increase in 
overall immune mediator profiles (figure 13C), however none of the changes in the LNG arm 




Figure 12. Magnitude of change in principal component estimates for pro-inflammatory cytokine profiles 
(A), chemokine profiles (B) and overall cytokine profiles (C) between baseline and one month after 
contraceptive initiation. Genital immune mediator concentrations in lateral vaginal wall swabs were measured 
using Luminex. Principal component analysis was used to group pro-inflammatory cytokines and chemokines and 
to generate estimates for each group. Baseline estimates were subtracted from month one estimates to generate 
the magnitude of change. Mann-Whitney U test was used for comparison of estimates between contraceptive 
arms. Abbreviations: Cu-IUD, Copper intrauterine device; DMPA-IM, intramuscular depo-medroxyprogesterone 
acetate; LNG, levonorgestrel. P<0.05 were considered statistically significant.  
Figure 13. Magnitude of change in principal component estimates for pro-inflammatory cytokine profiles 
(A), chemokine profiles (B) and overall cytokine profiles (C) between baseline and three months after 
contraceptive initiation. Genital immune mediator concentrations in lateral vaginal wall swabs were measured 
using Luminex. Principal component analysis was used to group pro-inflammatory cytokines and chemokines and 
to generate estimates for each group. Baseline estimates were subtracted from month three estimates to generate 
the magnitude of change. Mann-Whitney U test was used for comparison of estimates between contraceptive 
arms. Abbreviations: Cu-IUD, Copper intrauterine device; DMPA-IM, intramuscular depo-medroxyprogesterone 




Exploratory PCA was performed using the log-transformed FC values of all pro-inflammatory 
and chemotactic cytokines, as well as IFN-α. One-month following contraceptive initiation, 
Principal component 1 (PC1) explained 40% of the variation in immune mediators while PC2 
explained 14% (figure 14A). Immune mediators most strongly associated with PC1 at one 
month post contraceptive initiation included IL-8, IL-1β, MIP-3α, IL-6 and MIP-1α (figure 
14C). While these loadings were all positive, RANTES, IL-8, MIP-1β, IL-1β and MIP-3α 
loaded negatively on PC2. Positive associations with PC2 at one month following contraceptive 
initiation were observed for TNF-α, IP-10, MIP-1α and IFN-α (figure 14D). Copper IUD users 
had higher scores on PC1 than DMPA-IM and LNG implant users one month following 
contraceptive initiation, resulting in the copper IUD cluster being shifted to the right compared 
to those of DMPA-IM and LNG users (figure 14A). This indicates that concentrations of the 
cytokines associated with PC1 tended to be higher in copper IUD users compared to those of 
DMPA-IM and LNG users.  
Three months following contraceptive initiation, PC1 explained 42% of the variation in 
immune mediators, while PC2 explained 12% (figure 14B). The strongest positive associations 
between immune mediators and PC1 were observed for IL-8, IL-6, MIP-3α, IL-1β, IP-10 and 
MIP-1α (figure 14E). TNF-α, IFN-α, IP-10 and MIP-1β loaded negatively on PC2, while MIP-
1β, IL-1β, RANTES, IL-8, IL-6 and MIP-3α were positively associated with PC2 (figure 14F). 
Similar to one month post contraceptive initiation, copper IUD use was associated with higher 
scores on PC1 relative to DMPA-IM use three months following insertion. Additionally, LNG 
implant users shifted to the right, indicating raised levels of immune mediators positively 
associated with PC1 (figure 14B). However, it is worth noting that changes in cytokine profiles 




Figure 14. Principal component analysis (PCA) of log10-transformed fold changes in immune mediator 
concentrations one- (A) and three- (B) months post contraceptive initiation. PCA was conducted using the R 
mixOmics package. Contraceptive methods are represented by colours and shapes, with copper IUD as blue 
circles, DMPA-IM as orange triangles and LNG implant as grey crosses. (C) The immune mediators most strongly 
associated with PC1 one month following contraceptive initiation included several chemokines (IL-8, MIP-3α 
and MIP-1α) as well as pro-inflammatory cytokines (IL-1β and IL-6). (D) The immune mediators that loaded 
positively on PC2 one month following contraceptive initiation included a pro-inflammatory cytokine (TNF-α) 
and chemotactic cytokines (IP-10 and MIP-1α) as well as IFN-α. Cytokines that were negatively associated with 
PC2 included RANTES, pro-inflammatory cytokines (IL-6 and IL-1β) as well as chemokines (MIP-1β and MIP-
3α). (E) The immune mediators most strongly associated with PC1 three months following contraceptive initiation 
similarly included chemotactic cytokines (IL-8, MIP-3α, IP-10 and MIP-1α) and pro-inflammatory cytokines (IL-
6 and IL-1β). (F) The immune mediators that loaded positively on PC2 included chemokines (MIP-1β and IL-8) 
and pro-inflammatory cytokines (IL-1β, IL-6). Cytokines that were negatively associated with PC2 included the 






C D E F 
48 
 
Figure 14 continued. Abbreviations: TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage 
inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, interferon-alpha, SLPI, secretory leukocyte 
protease inhibitor; RANTES, regulated on activation, normal T cell expressed and secreted.   
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Unsupervised hierarchical clustering  
Unsupervised hierarchical clustering was used to visualize variation in inflammatory (TNF-α, 
IL-6 and IL-1β) and chemokine (IL-8, MIP-1α, IP-10, MIP-3α, MIP-1β and RANTES) 
concentrations in individual women and to cluster women according to the similarities in their 
immune mediator expression profiles. Figure 15 shows heat maps of the log10-transformed FC 
values for each cytokine (columns) per individual (rows) one- (figure 15A) and three- months 
(figure 15B) post contraceptive initiation. The contraceptive method of each woman is 
indicated by a colour. The dendrogram above the heat map illustrates degrees of relatedness 
between genital cytokine profiles evident within the various women. While the length of 
horizontal branches has no meaning, vertical lines visualize the degree of cytokine relatedness, 
with longer branches indicating more distant relationships. The dendrogram on the left-hand 
side of the heat map indicates relationships between the expression profiles of the analysed 
cytokines across all women assessed in this study. Horizontal lines are a measure of the degree 
of similarity between the cytokine expression profiles of the individual women while vertical 
lines represent arbitrary lengths. At one-month following contraceptive initiation, the 
expression of IP-10, MIP-1α and TNF-α, as well as MIP-1β, MIP-3α, IL-6, IL-8 and IL-1β 
were more closely related, while the expression of RANTES proved to be more unique. The 
expression of the cytokines IP-10, MIP-1α and TNF-α as well as MIP-3α, IL-6, IL-8 and IL-
1β remained closely related three months post contraceptive initiation. Additionally, RANTES 
and MIP-1β expression showed a high degree of relatedness.  
Copper IUD use tended to be associated with higher levels of cytokines one- and three- months 
post contraceptive initiation (figure 15A, 15B). Women using DMPA-IM did not cluster 
together one month after DMPA-IM injection (figure 15A) but tended to cluster towards the 
bottom of the heat map three months following contraceptive initiation. While LNG implant 
use was associated with lower cytokine levels one month following insertion (figure 15A), a 
higher proportion of LNG implant users had elevated cytokine levels three months post 





Figure 15. Unsupervised hierarchical clustering of women according to the similarities of their immune 
mediator expression profiles. Cytokine profiles were assessed in lateral vaginal wall swab samples from women 
using the copper IUD (n=55; blue blocks), DMPA-IM (n=53; orange blocks) and the LNG implant (n=59; green 
blocks) one month (A) and three months (B) following contraceptive initiation. Variations in cytokine fold 
changes are indicated using a colour scale that ranges from blue (low) through white to red (high). The dendrogram 
above the heat map illustrates degrees of relatedness between genital cytokine profiles. The dendrogram on the 
left-hand side of the heat map indicates relationships between the expression profiles of the analysed cytokines 
across all women assessed in this study. Abbreviations: TNF-α, tumour necrosis factor-alpha; IL, interleukin; 
MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; RANTES, regulated on 
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Longitudinal changes in immune mediators  
Mixed effects linear regression analysis using log10-transformed immune mediator data was 
performed to assess changes in immune mediator concentrations over time. Table 3 shows the 
analysis of copper IUD users relative to DMPA-IM users. A mixed effects linear regression 
analysis was selected to enable inclusion of participants with missing data. This approach 
allowed for analysis of longitudinal changes in cytokine measurements between arms, rather 
than comparison of absolute differences between individual time points. The β coefficient 
indicates the degree of change of an immune mediator in copper IUD users relative to DMPA-
IM use, with a positive value showing a greater increase in cytokine concentration. Overall, 
concentrations of immune mediators tended to increase in copper IUD users relative to DMPA-
IM users. The magnitude of change of all immune mediators was greater in copper IUD users 
between one month and baseline compared to DMPA-IM users, with the exception of IFN-α 
and MIP-1α which showed very little change. Similarly, the concentrations of most immune 
mediators tended to show a greater degree of change in copper IUD users three-months 
following contraceptive initiation when compared to DMPA-IM use, although the magnitude 
of change was small for TNF-α, IL-8, MIP-1 α, IFN-α, SLPI and RANTES. The biggest 
increase in immune mediator concentration in copper IUD users was observed for the 
chemotactic cytokine IP-10 with significant 0.404 and 0.384 log10 pg/ml increases one- and 
three- months after insertion relative to DMPA-IM users, respectively. The pro-inflammatory 
cytokine IL-6 and the chemokine MIP-1β also showed significantly greater increases in copper 
IUD compared to DMPA-IM users, both one- and three months following contraceptive 
initiation. A statistically significantly larger increase in TNF-α levels was observed in copper 
IUD compared to DMPA-IM users after one month of contraceptive use.  
Results of the mixed effects linear regression analysis comparing LNG implant users to 
DMPA-IM users are presented in table 4. Although the changes in concentrations of IP-10 and 
SLPI tended to be greater in women using the LNG implant one month post contraceptive 
initiation when compared to DMPA-IM users, this was not statistically significant. The pro-
inflammatory IL-1β and the chemotactic MIP-1α showed a non-significant trend towards a 
greater reduction in concentrations between month 1 and baseline in LNG implant users 
compared to women using DMPA-IM. While similar trends were observed at three months 
following contraceptive initiation, with TNF-α, IP-10, MIP-3α, SLPI and RANTES showing 
greater increases and IL-1β showing a smaller increase in LNG implant users compared to 
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women using DMPA-IM. Differences in the magnitude of change were only statistically 
significant for IP-10 and SLPI.  
 
 
Table 3. Mixed effects linear regression analysis of changes in immune mediator concentrations in copper 

















Shaded cells indicate significant p values (p < 0.05). Abbreviations: TNF-α, tumour necrosis factor-alpha; IL, 
interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, Interferon-
alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell expressed 
and secreted.  
Immune mediator β coefficient p value 95% Confidence Interval 
TNF-α 
Month 1 0.198 0.037 0.012 - 0.383 
Month 3 0.090 0.333 -0.092 - 0.272 
IL-6 
Month 1 0.198 0.045 0.004 - 0.393 
Month 3 0.214 0.028 0.024 - 0.405 
IL-1β 
Month 1 0.226 0.149 -0.081 - 0.532 
Month 3 0.217 0.158 -0.084 - 0.052 
IL-8 
Month 1 0.183 0.251 -0.130 - 0.496 
Month 3 -0.003 0.982 -0.311- 0.304 
MIP-1α 
Month 1 0.040 0.824 -0.309 - 0.388 
Month 3 -0.056 0.750 -0.400 - 0.287 
IP-10 
Month 1 0.404 0.029 0.042 - 0.766 
Month 3 0.384 0.034 0.029 - 0.739 
MIP-3α 
Month 1 0.324   0.111     -0.074 - 0.722 
Month 3 0.177  0.375     -0.214 - 0.569 
IFN-α 
Month 1 -0.026 0.637 -0.134 - 0.082 
Month 3 0.040 0.462 -0.066 - 0.146 
SLPI 
Month 1 0.287 0.064 -0.016 - 0.591 
Month 3 0.096 0.527 -0.202- 0.395 
RANTES 
Month 1 0.215 0.149 -0.077 - 0.507 
Month 3 0.092 0.532 -0.196 - 0.379 
MIP-1β 
Month 1 0.241 0.026 0.029 - 0.453 
Month 3 0.213 0.046 0.004 - 0.421 
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Table 4. Mixed effects linear regression analysis of changes in immune mediator concentrations in LNG 
















Shaded cells indicate significant p values (p < 0.05). Abbreviations: TNF-α, tumour necrosis factor-alpha; IL, 
interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, Interferon-
alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell expressed 
and secreted. 
  
Immune mediator β coefficient p value 95% Confidence Interval 
TNF-α 
Month 1 0.059 0.501 -0.110 - 0.225 
Month 3 0.135 0.110 -0.030 - 0.300 
IL-6 
Month 1 -0.046 0.625 -0.232 - 0.139 
Month 3 0.053 0.571 -0.130 - 0.236 
IL-1β 
Month 1 -0.151 0.281 -0.425- 0.123 
Month 3 -0.156 0.258 -0.425 - 0.114 
IL-8 
Month 1 -0.024 0.880 -0.338 - 0.290 
Month 3 -0.044 0.781 -0.354 - 0.266 
MIP-1α 
Month 1 -0.192 0.275 -0.535 - 0.152 
Month 3 -0.001 0.995 -0.341 - 0.339 
IP-10 
Month 1 0.143 0.347 -0.156- 0.443 
Month 3 0.4401 0.003 0.146 - 0.735 
MIP-3α 
Month 1 0.032 0.865 -0.341 - 0.406 
Month 3 0.327 0.081 -0.041 - 0 .695 
IFN-α 
Month 1 -0.042 0.431 -0.145 - 0.062 
Month 3 0.039 0.449 -0.062- 0.141 
SLPI 
Month 1 0.192 0.202 -0.103 - 0.487 
Month 3 0.370 0.013 0.079 - 0 .660 
RANTES 
Month 1 0.041 0.775 -0.240 - 0.322 
Month 3 0.159 0.260 -0.118 - 0.437 
MIP-1β 
Month 1 -0.031 0.754 -0.2258 - 0.163 
Month 3 0.002 0.985 -0.189 - 0.193 
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Changes in cytokine concentrations after adjustment for potential confounders 
Multinomial logistic regression analysis using log10-transformed FC in immune mediator 
concentrations was performed to compare changes in immune mediator concentrations in 
copper IUD and LNG implant users relative to DMPA-IM use, after adjusting for possible 
confounders, including site, age and infection status with chlamydia, gonorrhoea and HSV-2. 
PSA presence was not controlled for in this model, as it was not identified as a potential 
confounder in the baseline analysis. Multinomial logistic regression is used to predict 
categorical placement in a dependent variable based on multiple independent variables 118. For 
example, with reference to the data presented in table 5, if the log10-transformed FC of IP-10 
increased by 1 unit at one month following copper IUD insertion, the multinomial log-odds 
ratio for being a copper IUD user, relative to the log-odds ratio of being a DMPA-IM user, 
would be expected to increase by 0.623 units while holding all other variables in the model 
constant (table 5). Significant increases associated with copper IUD compared to DMPA-IM 
use were observed for the pro-inflammatory cytokine IL-6 and the chemokine IP-10 at one- 
and three- months following contraceptive initiation after controlling for site, age and infection 
status with chlamydia, gonorrhoea and HSV-2 (table 5). LNG implant use, relative to DMPA-
IM use, was associated with higher levels of IP-10 and SLPI three months following 




Table 5. Multinomial logistic regression analysis of changes in immune mediator concentrations in copper 
IUD compared to DMPA-IM users one- and three- months following contraceptive initiation.   
Immune 
mediator 




Month 1 0.962 0.035 0.068 - 1.856 0.065 
Month 3 0.467 0.284 -0.387 - 1.321 0.405 
IL-6 
Month 1 0.787 0.062 -0.038 - 1.613 0.041 
Month 3 0.804 0.039 0.041 - 1.566 0.021 
IL-1β 
Month 1 0.421 0.109 -0.095 - 0.937 0.094 
Month 3 0.350 0.157 -0.135 - 0.836 0.093 
IL-8 
Month 1 0.705 0.289 -0.239 - 0.804 0.338 
Month 3 -0.011 0.960 -0.450 - 0.428 0.913 
MIP-1α 
Month 1 0.059 0.793 -0.378 - 0.495 0.865 
Month 3 -0.063 0.782 -0.508 - 0.382 0.965 
IP-10 
Month 1 0.623 0.018 0.105 - 1.140 0.038 
Month 3 0.478 0.031 0.045 - 0.912 0.029 
MIP-3α 
Month 1 0.365 0.113 -0.087 - 0.817 0.162 
Month 3 0.159 0.400 -0.212 - 0.530 0.368 
IFN-α 
Month 1 -0.531 0.501 -2.078 - 1.016 0.524 
Month 3 0.522 0.462 -0.870 - 1.914 0.385 
SLPI 
Month 1 0.500 0.054 -0.009 - 1.010 0.111 
Month 3 0.181 0.471 -0.313 - 0.675 0.548 
RANTES 
Month 1 0.417 0.144 -0.142 - 0.977 0.100 
Month 3 0.137 0.581 -0.351 - 0.625 0.509 
MIP-1β 
Month 1 0.743 0.041 0.031 - 1.454 0.051 
Month 3 0.728 0.044 0.020 - 1.436 0.059 
 
The confounders included in this model were site, age and infection status with chlamydia, gonorrhoea and HSV-
2. Shaded cells indicate significant p values (p < 0.05). Abbreviations: HSV-2; herpes simplex virus type 2, TNF-
α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ 
inducible protein-10; IFN-α, Interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated 





Table 6. Multinomial logistic regression analysis of changes in immune mediator concentrations in LNG 
implant compared to DMPA-IM users one- and three- months following contraceptive initiation.   
Immune 
mediator 




Month 1 0.245 0.552 -0.562- 1.051 0.804 
Month 3 0.705 0.110 -0.160 - 1.569 0.142 
IL-6 
Month 1 -0.248 0.560 -1.080 - 0.585 0.675 
Month 3 0.216 0.577 -0.544 - 0.976 0.313 
IL-1β 
Month 1 -0.227 0.369 -0.724 - 0.269 0.362 
Month 3 -0.257 0.281 -0.724 - 0.210 0.396 
IL-8 
Month 1 -0.115 0.651 -0.616 - 0.385 0.539 
Month 3 -0.062 0.778 -0.495 - 0.371 0.853 
MIP-1α 
Month 1 -0.244 0.271 -0.679 - 0.191 0.152 
Month 3 0.011 0.962 -0.430 - 0.452 0.908 
IP-10 
Month 1 0.190 0.438 -0.289 -0 .669 0.763 
Month 3 0.562 0.011 0.127 - 0.996 0.012 
MIP-3α 
Month 1 -0.018 0.936 -0.448 - 0.412 0.724 
Month 3 0.309 0.102 -0.062 - 0.679 0.076 
IFN-α 
Month 1 -0.776 0.316 -2.294 - 0.742 0.375 
Month 3 0.513 0.464 -0.861 - 1.888 0.328 
SLPI 
Month 1 0.301 0.228 -0.188 - 0.790 0.417 
Month 3 0.661 0.012 0.147 - 1.174 0.012 
RANTES 
Month 1 0.071 0.800 -0.478 - 0.620 0.571 
Month 3 0.264 0.281 -0.216- 0.744 0.228 
MIP-1β 
Month 1 -0.134 0.697 -0.810 - 0.541 0.706 
Month 3 0.012 0.972 -0.679 - 0.704 0.969 
 
The confounders included in this model were site, age and infection status with chlamydia, gonorrhoea and HSV-
2. Shaded cells indicate significant p values (p < 0.05). Abbreviations: HSV-2; herpes simplex virus type 2; TNF-
α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ 
inducible protein-10; IFN-α, Interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated 





Immune mediator profiles in the FGT are thought to play an important role in the HIV risk of 
women. The effects of long-acting contraceptives, including DMPA-IM, the copper IUD and 
the LNG implant, on these cytokine profiles (and by extension HIV risk) remain largely 
unknown. The focus of this study was to investigate changes in immune mediator profiles 
associated with the initiation of DMPA-IM and compare these to LNG implant and copper IUD 
insertion. Furthermore, baseline demographic and biological factors that may alter immune 
mediator responses to these methods of contraception were evaluated. Correlates of immune 
mediator concentrations at baseline included clinical site, age and HSV-2 seropositivity. The 
copper IUD and LNG implant were associated with rapid increases in inflammatory markers 
following contraceptive initiation, while no significant changes were detected following 
DMPA-IM initiation. After adjusting for potential confounders, including site, age and 
infection status with chlamydia, gonorrhoea and HSV-2, IL-6 and IP-10 were significantly 
elevated in the copper IUD compared to the DMPA-IM arm at months 1 and 3, while IP-10 
and SLPI were higher in the LNG implant arm at month 3 compared to the DMPA-IM arm. 
Quality of mediator data 
Generally, strong positive correlations were observed between duplicate immune mediator 
measurements. However, a high proportion of MIP-1β and RANTES concentrations were 
undetectable. Analysis of the standard curves generated during Luminex revealed that the lower 
detection limit was likely too high to reliably identify lower concentrations of these cytokines. 
Additionally, there is little consensus on the best method of mucosal sampling119. It has 
previously been suggested that endocervical swabs and cervicovaginal lavage (CVL) samples 
are optimal for maximum recovery of mediators in the FGT120. This could explain the low 
levels of MIP-1β and RANTES observed in this study, where lateral vaginal wall swabs were 
used. While the two cytokines were included in the downstream analysis, results should be 
interpreted with caution. The remaining immune mediators assessed in this study showed high 
correlation between duplicate values and detection levels were above 70%.  
Baseline correlates of FGT immune mediator profiles  
In this study, it was found that concentrations of the pro-inflammatory cytokine IL-6 and the 
chemokine MIP-3α were significantly higher in women from SRC, located in Pretoria, when 
compared to those from MRU, Durban. Previous studies in women from different locations 
within South Africa identified significant differences in the vaginal microbiome and hence 
inflammation levels. Lennard, et al. found that the prevalence of STIs was significantly higher 
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in women from Cape Town compared to those from Johannesburg6. The prevalence of C. 
trachomatis, in particular, was determined to be 3-fold higher in women from Cape Town. 
Although no differences in the prevalence of the STIs that were assessed in this study were 
found between the two sites, it is possible that the prevalence of other STIs, e.g. Trichomonas 
vaginalis, or BV differed. Another possibility is that there were slight differences in sampling 
methods between the two sites.  
PSA is frequently measured as a biomarker of recent seminal plasma exposure121. The presence 
of this protein was not associated with significant differences in immune mediator 
concentrations, but the pro-inflammatory IL-6 and the chemotactic cytokine MIP-3α were 
slightly raised in its presence. While baseline PSA levels were significantly higher in women 
from the MRU, Durban, women from SRC showed higher concentrations of the protein at both 
follow up visits. Thus, women enrolled at SRC demonstrated more frequent unprotected sexual 
activity close to their study visits overall. A study of healthy Belgian women recently reported 
on a strong correlation between PSA and IL-6122. In addition, it has been shown that seminal 
plasma stimulates the production of several pro-inflammatory and chemotactic cytokines in the 
FGT, including IL-8, MCP-1 and GM-SCF in cervical cells lines34. The lack of significant 
associations between PSA and cytokines in this study may be due to the relatively small number 
of women who had detectable PSA in their FGT samples. However, based on this data, it seems 
that differences in sexual activity did not explain the differences in cytokine concentrations 
that were observed between study sites. 
Women in the age groups of 18-20 and 21-24 years had elevated concentrations of pro-
inflammatory IL-1β and the chemokines IL-8 and MIP-1α after adjusting for multiple 
comparisons. No significant differences in age was found between the two sites (figure S9). 
Importantly, an association between cytokine levels and age has been demonstrated previously 
in South African women, with younger women displaying higher inflammatory cytokine 
concentrations4. The study performed by Masson, et al. showed that elevated IL-6, IP-10, 
MCP-1 and MIP-1β concentrations were significantly associated with younger age. These 
results overlap with the association of young age and elevated immune mediator levels 
observed in this study. It has been suggested that, compared to adult women, the adolescent 
FGT is in a naïve state and immune responses to exogenous factors could be heightened in 
young women. While the role of HC use in women of different ages remains to be explored in 
the context of genital inflammation, studies have examined semen as an exogenous factor123. 
Generally, the immune system must be able to distinguish between semi-allogeneic semen from 
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sexual partners and potential pathogens for reproduction to be possible124. While semen should 
be tolerated, an inflammatory response must be mounted against pathogens. However, studies 
have shown that increased inflammation is observed in the genital tracts of women following 
semen exposure after a period of abstinence compared to women who were not abstinent34. 
Similarly, it is now hypothesized that the naïve state of the adolescent genital tract results in a 
lack of tolerance towards sex and semen, and exposure to these may result in a greater 
inflammatory response than seen in adult women125. Although it would be interesting to 
examine interactions between semen exposure and age that may influence cytokine 
concentrations, the relatively small number of PSA positive women in this study limited the 
power to conduct this analysis. 
Women who tested positive for HSV-2 tended to have lower concentrations of immune 
mediators at baseline. All immune mediators, with the exception of MIP-1β, were present at 
lower concentrations in HSV-2 seropositive women, however, this trend was only statistically 
significant for the chemokine MIP-1α after adjusting for multiple comparisons. This is 
surprising given that previous studies have found that HIV target cell concentrations at the 
mucosa are increased during HSV-2 infection, regardless of the presence of lesions39 and that 
subclinical levels of inflammation in the genital mucosa can persist for months after lesion 
resolution40. Infection status with C. trachomatis had a varied effect on immune mediator 
concentrations with some, including IL-1β, IL-8, MIP-1α, IP-10 and MIP-1β slightly raised in 
women who tested positive for the pathogen. Others, namely TNF-α, IL-6, MIP-3α, IFN-α and 
SLPI, were detected at lower levels in infected women, however, none of these associations 
remained significant after adjusting for multiple comparisons. Immune mediator 
concentrations were generally higher in women infected with N. gonorrhoeae, particularly, IL-
6 and IL-8, however, this trend was also not statistically significant after adjusting for multiple 
comparisons. Previously, Masson et al. showed that women with the above STIs had elevated 
concentrations of several pro-inflammatory and chemotactic cytokines compared to women 
with no infections. Women with chlamydia, gonorrhoea or shedding HSV-2 had upregulated 
concentrations of cytokines that mediate chemotaxis of several immune cells, including T cells, 
natural killer cells, phagocytes, monocytes, dendritic cells, neutrophils, eosinophils, 
granulocytes and endothelial cells. Furthermore, cytokines involved in cellular apoptosis, 
viability, activation, proliferation and differentiation were upregulated in women with 
chlamydia, gonorrhoea and shedding HSV-2. The study did not however identify any 
associations with HSV-2 seropositivity36. Chlamydia infection has shown a strong association 
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with elevated levels of cytokines in numerous studies36,126–128; and while no significant 
associations were detected in the present study, the concentrations of several chemotactic 
cytokines tended to be elevated in women who tested positive for the pathogen. Interestingly, 
Barnabas et al. recently reported that C. trachomatis infection was associated with higher 
genital inflammation in women from Johannesburg compared to women from Cape Town129. 
This was due to clade differences – some clades of C. trachomatis proved to be more 
inflammatory than others. In this study, no difference in immune mediator levels was detected 
between C. trachomatis positive women from Durban compared to Pretoria (figure S8). It has 
been shown that infection of cervical and vaginal cell lines with N. gonorrhoeae resulted in 
upregulated IL-1, IL-6 and IL-8 production130. The cytokines IL-6 and IL-8 are under the 
transcriptional control by NF-κB and, while the former is a powerful chemoattractant and 
activator of neutrophils 131, the latter is considered one of the most potent cytokines in 
promoting inflammatory events through recruitment and activation of T cells and 
differentiation of B cells132. Although chlamydia and HSV-2 seropositivity were prevalent in 
this cohort, very few women had gonorrhoea (n=7), limiting the statistical power of this 
analysis. Mucosal cytokine production forms a central part of the immune response to 
pathogens in the vaginal environment and future studies to investigate broader immune 
pathways that drive these cytokine responses could provide crucial insight into the impact of 
STIs on the genital milieu133,134.  
Changes in FGT immune mediator concentrations associated with contraceptive use 
While the benefits of HCs are immense, their role in HIV acquisition risk has long been 
discussed. Although the recent ECHO trial did not demonstrate statistically significant 
differences of HIV infection between women using DMPA-IM compared to those using the 
copper IUD or the LNG implant, the study was only powered to detect an increased risk above 
50% and it furthermore remains unknown whether these forms of HCs increase HIV risk 
relative to other forms of contraception or no contraception78. Evaluation of the changes in the 
profiles of immune mediators that have previously been linked to HIV acquisition risk may 
provide further insight into the possibility of increased risk associated with these 
contraceptives. 
Copper IUD 
In this study, copper IUD use was associated with rapid increases of inflammatory markers 
following contraceptive initiation. Pro-inflammatory IL-6 and IL-1β and chemotactic IL-8, 
MIP-1⍺, IP-10, and MIP-1β were significantly elevated one month following copper IUD 
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insertion. Although to a lesser extent, concentrations of the pro-inflammatory IL-6 and 
chemotactic IP-10 remained significantly elevated after three months following copper IUD 
insertion. In line with this, using PCA estimates, it was found that overall pro-inflammatory, 
as well as chemotactic cytokine, profiles were significantly raised in copper IUD users 
compared to DMPA-IM and LNG implant users, particularly one-month post contraceptive 
initiation. In an exploratory PCA analysis, copper IUD users had higher scores on PC1, (onto 
which IL-8, IL-1β, MIP-3α, IL-6 and MIP-1α loaded positively), than DMPA-IM and LNG 
implant users one month following contraceptive initiation. This trend persisted until three 
months post contraceptive initiation. Unsupervised hierarchical clustering analysis further 
substantiated this observation as copper IUD use was again found to be associated with higher 
levels of cytokines one- and three- months post contraceptive initiation.  
Importantly, a number of cytokines that were found to be present at higher concentrations 
following copper IUD use in this study have been identified as some of the most critical 
cytokines associated with HIV infection risk4. These include IL-8, MIP-1α and IP-10. IP-10, 
MIP-1α and MIP-1β are chemotactic for potential HIV target cells, including T cells, 
monocytes, macrophages, and dendritic cells9,135,136. Additionally, MIP-1α and MIP-1β bind 
directly to the CCR5 and therefore specifically target CCR5+ cells for recruitment to the genital 
mucosa22. The coreceptor plays a critical role in HIV transmission infection in the context of 
sexual transmission as infection is established exclusively by R5-tropic viruses23. Elevated 
levels of these cytokines are therefore proposed to increase recruitment of HIV target cells to 
the genital mucosa, in turn possibly increasing the likelihood of infection. The cytokines IL-6 
and IL-8 play a vital role in initiating the inflammatory response and regulate the host defence 
against pathogens, mediating the innate immune response. Evidence has suggested that 
dysregulation of systemic IL-6 production is a major contributor to the pathogenesis of chronic 
inflammation137. In the context of HIV transmission, it has been demonstrated that high 
concentrations of IL-6 increase HIV expression in vivo60.  Furthermore, HIV shedding was 
heightened in the presence of elevated IL-6 levels in cervicovaginal lavage obtained from HIV 
infected women58. The chemotactic cytokine IL-8 has also been associated with up to an 8-fold 
increase in HIV transmission in cervical explant tissue61,138. In addition, pro-inflammatory 
cytokines promote the expression of nuclear factor (NF)-κB. This influential transcription 
factor, in turn, directly binds to the HIV promoter and enhances its transcriptional capacity, 
thereby promoting productive infection further24.  
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Although there is a lack of available data, a recent pilot study assessed changes in 
cervicovaginal cytokine levels following the insertion of different intrauterine devices. The 
authors reported that copper IUD insertion induced a typical mucosal inflammatory cytokine 
response one month following insertion, characterised by significant increases in IL-1α, IL-1β, 
IL-6 and TNF-α139. Since the copper IUD is a non-hormonal method of contraception, the 
possible mechanisms behind increased genital inflammation are relatively unexplored. Older 
studies have reported increased cervical immunoglobulin levels in women using the copper 
IUD140. IgG, IgA and IgM levels were raised four months following copper IUD insertion. It 
was suggested that this could be due to a reaction whereby the host recognizes the contraceptive 
as a foreign body, eliciting an immune response or the increased presence of non-optimal 
bacteria following insertion140. In the past, results emerging from studies assessing the impact 
of the copper IUD on the vaginal microbiome have been inconsistent. In 2018, Achilles et al. 
reported an increase in BV rates in women using the copper IUD, suggesting that the IUD may 
increase colonization by BV-associated bacteria in the FGT110. Other studies did not establish 
a link between copper IUD use and changes in the vaginal microbiota141,142. As BV has been 
linked to an increased risk of STI infection, including HIV143, further investigations of whether 
and, if so, how the copper IUD impacts the vaginal microbiome are crucial.  
As previously discussed, genital inflammation is influenced by many factors, including age 
and STI status. In this study, concentrations of cytokines also differed between women from 
different locations. The significant association between copper IUD use and increased levels 
of IL-6 and IP-10 remained significant after adjusting for possible confounders, namely site, 
age and infection status with chlamydia, gonorrhoea and HSV-2. This result suggests that the 
copper IUD may have effects on genital immune mediator profiles regardless of location, age 
and STI presence. 
The increase in both pro-inflammatory, as well as chemotactic cytokines that have been 
previously linked to increased HIV risk following copper IUD insertion suggests that HIV 
acquisition risk may be heightened in women using this type of contraceptive. The mechanism 
behind this may likely be a combination of increased cell target recruitment, promotion of HIV 
replication and epithelial barrier disruption that are favourable for the establishment of HIV 
infections. It is important to note that studies assessing the effects of HCs on FGT immunity in 
the context of HIV risk have used the copper IUD as a non-hormonal control 144. Given the 
results of this study, the reliability of this is questionable as immune profiles were significantly 




DMPA-IM is the most commonly used form of HC in sub- Saharan Africa, the area with the 
highest worldwide HIV-1 prevalence, and epidemiological studies have linked its use to an 
increased HIV risk74. In this study, initiation of DMPA-IM was not associated with any 
significant changes in immune mediator concentrations. One-month following contraceptive 
initiation, a slight decrease in SLPI concentrations was observed, however this change was not 
significant. Three months following DMPA-IM initiation, levels of IFN-α were slightly 
decreased, but this was not upheld after adjusting for multiple comparisons. Although no 
substantial changes in immune mediator profiles were detected following DMPA-IM use, the 
trend was towards an overall reduction. PCA and heat map analysis also showed an association 
with lower scores on PC1, again indicating immune mediator profiles were either slightly 
decreased or not changed following DMPA-IM initiation. 
SLPI, in particular, stood out as being reduced in DMPA-IM users one-month following 
initiation. SLPI is a major antimicrobial peptide that contributes to mucosal immunity in the 
FGT. This small protein has anti-inflammatory properties and is present in saliva, breast milk, 
genital tract secretions as well as semen. Importantly, at physiological concentrations, it is 
thought to possess potent anti-HIV-1 activity 145–147. For example, high levels of SLPI in HIV-
infected mothers have been associated with reduced HIV transmission during childbirth148. 
DMPA-IM use has previously been associated with decreased expression of SLPI in 
endometrial tissue149 and it is thought that other conditions associated with an increased HIV 
risk, such as HSV-2 infection and BV, may also downregulate SLPI expression150,151. In 
addition, a recent study by Morrison, et al., established a link between lower SLPI 
concentrations and HIV seroconversion18. Importantly, SLPI is primarily active against R5-
tropic viruses, which are responsible for sexual HIV transmission23,146. There is a lack of in 
vivo data for mechanisms underlying the antiviral potential of SLPI, however, it has been 
suggested that its ability to bind cellular cofactors supporting HIV infection of macrophages 
has inhibitory effects on the virus152. Although the picture is incomplete, the role of SLPI as a 
mediator of innate immunity and its anti-inflammatory potential suggests that a loss of SLPI 
might contribute to an increased risk of HIV acquisition. Interestingly, DMPA-IM use has also 
been linked to significant decreases in IFN-α levels due to reduced production of the immune 
mediator by dendritic cells153. In this study, concentrations of IFN-α were decreased three-
months following DMPA-IM initiation, although this did not remain significant after adjusting 
for multiple comparisons. Following SIV infection in rhesus macaques, IFN-α producing 
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dendritic cells accumulate rapidly beneath the genital mucosa135. While the mechanism behind 
this with regards to DMPA-IM use remains to be explored, suppression of IFN-α production 
may affect the immune system’s ability to control infection and thus benefit the virus153. 
While some animal studies have demonstrated the ability of MPA to suppress immune 
responses, both systemically and in the FGT103,154,155, few studies examining this relationship 
have been conducted in humans. MPA use has, however, been linked to a decrease in the 
production of several immune mediators, including IFN-α, IL-2, IL-4, IL-6, IL-12, TNF-α and 
MIP-1α, by peripheral blood cells and activated T cells153. In the context of FGT immunity in 
humans, Ngcapu, et al. have previously reported on a decrease of several pro-inflammatory as 
well as chemotactic cytokines following DMPA-IM use95. Although these associations 
potentially suggest that MPA can interfere with chemotaxis of potential HIV target cells, this 
must be explored further. Contrary to this down-regulation of immune mediators, some studies 
have reported on the inflammatory potential of DMPA-IM. Specifically, DMPA-IM use has 
been associated with increased levels of pro-inflammatory cytokines in vaginal fluids, 
including IL-6, RANTES, MIP-1α, MIP-1β and IP-10101. MPA was also shown to increase IL-
6 levels in a human vaginal cell line156.  
Importantly, suppression of the immune responses at the female genital mucosa may influence 
susceptibility to other infections that in turn may increase HIV infection risk. Studies in mice 
have shown that HSV-2 risk increases by up to 2-fold when treated with DMPA-IM108. 
Protection against STIs, most importantly HIV, requires a delicate balance of sufficient 
immune activity, while simultaneously regulating inflammatory conditions at the mucosal 
point of entry. To date, the effects of DMPA-IM on genial inflammation remain unclear. In the 
future, it will be important to explore the relationship between serum and local progestin 
concentrations following the use of MPA-based injectables and their effect on immune 
mediator profiles. The effects of MPA likely differ greatly between individuals as the local 
progestin concentrations depend on an array of factors, including the administered dosage, the 
route of administration as well as the drug metabolism of the individual73.  
LNG implant 
No changes in immune mediator concentrations were evident one-month post LNG insertion, 
however at three months, concentrations of TNF-⍺, IP-10, MIP-3⍺ and SLPI were significantly 
raised relative to baseline. This resulted in an overall raised immune mediator profile three 
months following LNG implant insertion. PCA indicated a shift towards higher concentrations 
of immune mediators positively loaded on PC1 three months following LNG implant insertion, 
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further substantiating this observation. Additionally, a higher proportion of women using LNG 
implant was associated with elevated cytokine levels following unsupervised hierarchical 
clustering in month three compared to month one. 
Tissue-specific and systemic effects in response to LNG implant use are poorly characterized, 
with no studies assessing changes in immune mediator concentrations. Initial interactions 
between HIV and mucosal immunity determine the outcome of the exposure in the context of 
sexual transmission. In order to establish an infection, the virus must cross the mucosal barrier. 
Physical disruptions in the epithelium can create gaps known as paracellular passages, through 
which the virus can reach the submucosa157. High levels of pro-inflammatory cytokines, 
including TNF-α, which was raised in LNG implant users in this study, can lead to 
reorganization of the actin-cytoskeleton and destabilization of tight junctions, leaving the 
mucosa vulnerable to infection157. A recent study showed that LNG reduced genital expression 
of the desmosomal cadherin desmoglein-1α (DSG1α) in mouse models96. Desmosomes are 
cellular structures specialized for cell-to-cell adhesion and therefore crucial to the integrity of 
the mucosal barrier158. Downregulation of these structures resulted in enhanced access of 
inflammatory cells to the genital mucosa by increasing mucosal epithelial permeability and 
thus led to an increased susceptibility to infections96. A second possible mechanism for 
establishment of infection is transcytosis. During this process, viral particles bind to molecules 
on the epithelial cell surface, are then internalized to form vesicles and can be transported into 
the intracellular environment. The presence of pro-inflammatory cytokines, including TNF-α, 
can trigger the release of virion particles from vesicular compartments at the intracellular space, 
allowing them to infect target cells at the lamina propria157. Although it is well described that 
TNF-α levels are raised during HIV exposure159,160, the presence of high levels of this cytokine 
could affect the mucosal barrier integrity, leaving the FGT vulnerable to infections including 
HIV. This vulnerability may be further enhanced by the presence of high levels of chemotactic 
cytokines, such as IP-10. As previously discussed, elevated levels of IP-10 are thought to 
increase target cell recruitment, providing more hosts to HIV and thus increasing the risk of 
infection.   
It is important to note that LNG implant use, relative to DMPA-IM use, remained significantly 
associated with higher levels of genital IP-10 and SLPI three months following contraceptive 
initiation after controlling for confounders (site, age and infection status with chlamydia, 
gonorrhoea and HSV-2). Although SLPI has been found to be protective against HIV infection 
at high levels in some studies145–147, a recent study reported that higher cervicovaginal lavage 
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concentrations of SLPI were associated with HIV seroconversion161 and another identified an 
association between lower SLPI concentrations and HIV seroconversion risk in a larger 
populations162. However, it has been suggested that higher levels of HIV-1 RNA in the FGT 
may induce epithelial cell expression of SLPI161. This means that the association between 
higher SLPI levels pre-infection and increased HIV acquisition risk could be due to HIV-1-
induced expression of SLPI by epithelial cells in women that have experienced repeated HIV 
exposure161. However, this idea needs to be explored further.   
The available data on the effects of LNG implant use on genital cytokine profiles are sparse, 
however, a recent meta-analysis suggested no link between LNG implant use and an increased 
risk of HIV acquisition74. Contrasting this, the results of this study indicate that LNG use may 
affect genital immune mediator levels, warranting further research.  
Limitations 
BV data was not available for this study and women were only tested for N. gonorrhoeae and 
C. trachomatis at baseline. Further testing for STIs and BV at all time-points will, however, be 
conducted on stored samples in the future. Additionally, this study only evaluated changes in 
immune mediators up to three months and it is therefore unclear whether the inflammatory 
responses observed would subside over a longer period of time.  
Conclusion 
The debate surrounding the effects of HCs on genital immune mediator profiles, and by 
extension HIV risk, is ongoing. This study did not establish a link between DMPA-IM use and 
significant changes in the concentrations of the genital immune mediators that were measured. 
Although not significant, the trend was towards a decrease in overall immune mediator profiles 
three months following DMPA-IM initiation. While results assessing the effects of HCs on 
genital cytokine profiles are inconsistent, this is particularly true for the injectable DMPA-IM. 
Some studies have reported an increase in concentrations of important genital immune 
mediators following DMPA-IM use131 and others have suggested the opposite95. In the future, 
the immunosuppressive potential of MPA should be assessed following the use of Sayana 
Press, a lower dose formula than DMPA-IM that is administered subcutaneously163.  
This study additionally showed that the copper IUD and LNG implant were associated with a 
rapid increase of immune mediator levels. Interestingly, IP-10 has been identified as one of the 
most critical cytokines elevated in women that later became HIV-infected4 and this chemokine 
was found to be elevated in both copper IUD and LNG implant users in this study. Its 
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chemotactic effects on HIV target cells in the genital mucosa could play an important role in 
the context of HIV acquisition risk. Recruitment of potential target cells could be further 
enhanced by the presence of high levels of other chemotactic cytokines, such as IL-8, MIP-1α 
and MIP-1β, as seen in copper IUD users, and MIP-3α, as seen in LNG implant users. In copper 
IUD users, the increase in chemokine levels was accompanied by significantly increased 
concentrations of the pro-inflammatory cytokine IL-6. As previously discussed, IL-6 is thought 
to play an important role in HIV risk by promoting mucosal inflammation and HIV 
expression60.  
Overall, this study has shown that both non-hormonal contraception in the form of the copper 
IUD and HCs, in this case the LNG implant, have the potential to alter immune mediator 
profiles in the FGT. HIV susceptibility in the FGT is known to be enhanced by several 
downstream effects of raised cytokine levels, including increased target cell recruitment and 
impaired mucosal barrier integrity. Furthermore, genital inflammation is thought to impair the 
effectiveness of HIV prevention methods19. More studies assessing the effects of contraceptive 
methods on genital inflammation and its downstream effects on HIV acquisition risk are needed 
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Luminex assay principle  
 
 
Figure S1. Luminex assay principle. Colour-coded magnetic microparticles (MP) that are pre-coated with 
immune mediator (IM)-specific antibodies are supplied by the manufacturer. Together with standards or samples 
and the specific antibodies, these microparticles are added to wells. The specific antibody binds to the analyte of 
interest. Substances that do not bind to the antibodies are washed off and biotinylated antibodies specific to the 
analytes of interest are added. A second wash removes unbound biotinylated (B) antibodies. Phycoerythrin (PE)-
conjugated streptavidin (S) is added and binds to the biotinylated detection antibodies. Unbound Streptavidin-PE 
is removed with a last wash. The microparticles are then resuspended in buffer to be read with a Luminex 
Analyzer. The microparticles are held in a monolayer with the use of a magnet and the beads are illuminated by 
2 Light Emitting Diodes (LEDs). One laser classifies the bead and determines the analyte that is being detected, 
while the other measures the magnitude of the PE-derived signal. The intensity is directly proportional with the 
amount of analyte that is bound. This information is recorded using a CCD camera. [(According to R&D Manual), 













Figure S2. Examples of Standard curves generated during Luminex. Genital immune mediator 
concentrations (pg/mL) in lateral vaginal wall swabs were measured using Luminex. Standards are displayed as 
blue rectangles, samples are represented by green triangles. Abbreviations: TNF-α, tumour necrosis factor-
alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, 
interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell 



































































































































































































































































































































Line graphs of genital immune mediator concentrations over time 
Figure S3 (A-K). Line graphs of genital immune mediator concentrations (pg/mL) at baseline, one month 
following insertion of Cu-IUD (m1) and three months following insertion of Cu-IUD (m3) (sample size, 
n=55). Genital immune mediator concentrations in lateral vaginal wall swabs were measured using Luminex. 
Wilcoxon signed rank test was used for comparisons and p-values were adjusted for multiple comparisons using 
a false discovery rate step-down procedure. Abbreviations: Cu-IUD, Copper intrauterine device; TNF-α, tumour 
necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible 
protein-10; IFN-α, interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated on 




Figure S4 (A-K). Line graphs of genital immune mediator concentrations (pg/mL) at baseline, one month 
following initiation of DMPA-IM (m1) and three months following initiation of DMPA-IM (m3) (sample 
size, n=53). Genital immune mediator concentrations in lateral vaginal wall swabs were measured using Luminex. 
Wilcoxon signed rank test was used for comparisons and p-values were adjusted for multiple comparisons using 
a false discovery rate step-down procedure. Abbreviations: DMPA-IM, intramuscular depomedroxyprogesterone 
acetate; TNF-α, tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, 
interferon-γ inducible protein-10; IFN-α, interferon-alpha, SLPI, secretory leukocyte protease inhibitor; 
RANTES, regulated on activation, normal T cell expressed and secreted. * Indicates p < 0.05 after adjusting for 






Figure S5 (A-K). Line graphs of genital immune mediator concentrations (pg/mL) at baseline, one month 
following insertion of LNG Implant (m1) and three months following insertion of LNG Implant (m3) 
(sample size, n=59). Genital immune mediator concentrations in lateral vaginal wall swabs were measured using 
Luminex. Wilcoxon signed rank test was used for comparisons and p-values were adjusted for multiple 
comparisons using a false discovery rate step-down procedure. Abbreviations: LNG, levonorgestrel; TNF-α, 
tumour necrosis factor-alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ 
inducible protein-10; IFN-α, interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated 




Log10-transformed fold change analysis of immune mediator data 
Figure S6 (A-K). Log10-transformed fold changes of genital immune mediator concentrations one month 
following initiation of contraceptive method in women using copper IUD (n=52), DMPA-IM (n=50) and LNG 
Implant (n=56). Genital immune mediator concentrations in lateral vaginal wall swabs were measured using 
Luminex. Mann-Whitney U test was used for comparisons and p-values were adjusted for multiple comparisons 
using a false discovery rate step-down procedure. Abbreviations: Cu-IUD, Copper intrauterine device; DMPA-
IM, intramuscular depo-medroxyprogesterone acetate; LNG, levonorgestrel; TNF-α, tumour necrosis factor-
alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, 
interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell 
expressed and secreted.   
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Figure S7 (A-K). Log10-transformed fold changes in genital immune mediator concentrations three months 
following initiation of contraceptive method in women using copper IUD (n=55), DMPA-IM (n=53) and LNG 
Implant (n=59). Genital immune mediator concentrations in lateral vaginal wall swabs were measured using 
Luminex. Mann-Whitney U test was used for comparisons and p-values were adjusted for multiple comparisons 
using a false discovery rate step-down procedure. Abbreviations: Cu-IUD, Copper intrauterine device; DMPA-
IM, intramuscular depo-medroxyprogesterone acetate; LNG, levonorgestrel; TNF-α, tumour necrosis factor-
alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, 
interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell 




Baseline immune mediator profiles of women positive for Chlamydia trachomatis 
 
 
Figure S8 (A-K). Baseline genital immune mediator profiles of women positive for Chlmaydia trachomatis, 
stratified by site. Genital immune mediator concentrations in lateral vaginal wall swabs were measured using 
Luminex. Women tested positive for Chlamydia were grouped by site; Setshaba Research Centre (blue; n=42) 
and MatCH Research Unit (pink; n=31). Mann-Whitney U test was used for comparisons. Abbreviations: SRC, 
Setshaba Research Centre (Pretoria); MRU, MatCH Research Unit (Durban); TNF-α, tumour necrosis factor-
alpha; IL, interleukin; MIP, macrophage inflammatory protein; IP-10, interferon-γ inducible protein-10; IFN-α, 
Interferon-alpha, SLPI, secretory leukocyte protease inhibitor; RANTES, regulated on activation, normal T cell 





Average age of women from SRU and MRU 
 
Figure S9. Average age of women from Setshaba Research Centre (blue, n=54) and MatCH Research Unit 
(pink, n=113). Mann-Whitney U test was used to compare groups. Abbreviations: SRC, Setshaba Research 
Centre (Pretoria); MRU, MatCH Research Unit (Durban). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
